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Extended spectrum (3-lactamases (ESBLs) were characterized in Salmonella 
spp. isolates from a pediatric ward of a hospital in Durban. Forty one Salmonella 
spp. were subjected to serotyping, antibiotic susceptibility testing, E-Tests for 
ESBL detection, iso-electric focusing, polymerase chain reaction for detection of 
genes and sequencing. Isolates were screened for the presence of WaTEM, 
WaSHV, WaCTX-M, WaOXA , WaCMY, WaDHA and WaACC genes. The most common 
serotype was Salmonella Typhimurium. Isolates were multi-drug resistant with 
100% susceptibility only to meropenem and ciprofloxacin. Tazobactam was the 
most effective inhibitor. Forty-one percent of the isolates were resistant to 
ceftriaxone, thus limiting therapeutic options for Salmonella infections.TEM-1 was 
the most predominant (3-lactamase found in 51% of isolates while SHV-12 found 
in 39 % was the most common ESBL. TEM-63 was evident in 29 %, TEM-116 in 
10 % and TEM-131 was found in one isolate. The high ceftazidime MICs of 
isolates expressing only TEM-63 were indicative of R164S substitution which 
widens the binding cavity to accommodate the bulky side chains of oxyimino-
aminothiazolyl cephalosporins. The identification of TEM-131 which differs from 
TEM-63 by 1 amino acid reiterates the evolutionary potential of the TEM-type p-
lactamase. Other ESBLs identified included SHV-2, CTX-M-3, CTX-M-15 and 
CTX-M-37. CMY-2 and the OXA-1 p-lactamase were also detected. This is the 
first report of TEM-116, CTX-M-3, -15 and -37 in Salmonella spp. in South Africa. 
All isolates with nalidixic acid MICs > 48 ug/ml had the mutation D87N, or D87G 
in the QRDR of the gyrA gene. This study showed that Salmonella spp. may be 
multi-drug resistant with the propensity to harbour p-lactamases in unique 
combinations. The diversity of ESBLs and the co-expression of quinolone 
resistance suggests that their incidence in salmonellae needs to be monitored. 
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CHAPTER ONE - INTRODUCTION 
1.1 Salmonella spp. 
Salmonella organisms are Gram-negative bacilli that belong to the 
Enterobacteriaceae family. Microbial taxonomists consider almost all of the 
Salmonella that infect mammals and birds to be one species (S. enterica), based 
on iso-enzymes, rRNA sequences, and DNA hybridization. There are six 
subspecies of S. enterica, viz., enterica (1), salamae (2), arizonae (3a), diarizonae 
(3b), houtenae (4), and indica (6). Within these six subspecies are over 2000 
serotypes of Salmonella determined by the carbohydrate structures and by flagella 
antigens. However, nearly all the serotypes that cause the disease in humans and 
domestic animals belong to subspecies enterica. Although closely related, there is 
enormous variation in the virulence and epidemiology of different serotypes of S. 
enterica. For instance, most serotypes cause only gastroenteritis, while specific 
serotypes cause enteric fever (Fierer and Guiney, 2001). 
1.2 Salmonellae Infections 
The World Health Organisation (WHO) in 2003 ranked infections as the leading 
global burden of disease and the leading cause of mortality in children 
(http://www.who.int/whr/2005/annexes-en.pdfAccesed 17 August 2008; Geddes et 
ai, 2007). Increasing antimicrobial resistance in non-typhoidal salmonellae (NTS) 
species has been a serious problem for public health worldwide. The high rate of 
resistance is hampering the use of conventional antibiotics, and there is growing 
resistance to newer antimicrobial agents (Su et ai, 2004). In developing countries 
NTS accounts for a steadily increasing proportion of human infections and 
represents about 20 - 30% of Salmonella serotypes, in particular multi-drug 
resistant Salmonella enterica serotype Typhimurium. The majority of 
extraintestinal NTS disease in African children occurs in infants and young children 
< 5 years old (Graham et ai, 2000; Wadula et ai, 2006). Outbreaks of NTS 
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predominantly present as a diarrheal disease acquired as food poisoning. In Africa 
the source and mode of transmission of Salmonella spp. is unclear and includes 
animals, animal products, water and infected humans. Young children may excrete 
the organism for up to 4 months. Outbreaks in hospitals and day-care centres 
support the existence of person-to-person spread which is associated with poor 
infection control and staff shortages. The clustering of patients in wards and the 
timing of presentation are associated with the spread of the organism (Wadula et 
a/., 2006). 
1.3 Antibiotic Use and Resistance in Salmonella spp. 
Although antibiotics are not usually recommended for Salmonella gastroenteritis, 
they are recommended for invasive Salmonella infection, e.g septicemia and 
meningitis which are common in infants, elderly and immunocompromised patients, 
particularly with human immunodeficiency virus (HIV). South Africa has the highest 
number of HIV-infected people in the world, with an estimated 5 million infected by 
the virus. Patients with HIV infection thus have an increased risk of invasive 
salmonellosis (Kruger et ai, 2004). 
Up to a decade ago, conventional 1st-line antimicrobial agents such as ampicillin, 
chloramphenicol, and cotrimoxazole were the drugs of choice for the treatment of 
life-threatening Salmonella infections in many countries and, still remain the main 
therapeutic drugs of choice in most resource constrained African countries. 
However in the past two decades, isolation of Salmonella spp. multiply resistant to 
these agents has been reported. In 2007 the Enteric Diseases Reference Unit of 
the National Institute for Communicable Diseases in South Africa reported 
resistance to five or more antimicrobial agents in 33.8 % (n = 1502) of NTS 
isolates (Keddy, 2008). The prevalence of extraintestinal Salmonella infections 
caused by antibiotic resistant Salmonella spp. in several geographic areas of the 
world is increasing. In these cases, fluoroquinolones and the third generation 
cephalosporins are recommended as alternatives, with ciprofloxacin being the drug 
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of choice (Rotimi et al., 2008). Widespread fluoroquinolone use in children has 
been discouraged because of the potential adverse effects on cartilage 
development. Therefore, extended-spectrum cephalosporins (especially 
cefotaxime or ceftriaxone), are the mainstay of treatment of serious infections due 
to NTS in children (Kruger et al., 2004). Recently, reports of growing resistance to 
these agents have appeared in the literature from different parts of the world 
(Rotimi et al., 2008). 
The emergence of multi-drug resistant Salmonella is widespread in Africa (Graham 
et al., 2000). In Zaire and Rwanda multi-drug resistant Salmonella Typhimurium 
were the predominant cause of bacteraemic illness in children, while in Kenya, this 
serotype was the main isolate in adults with salmonellae bacteraemia (Kariuki et 
al., 2005). A marked increase in disease caused by Salmonella Typhimurium 
occurred in Kenya during the 1970s. Among Algerian infants Salmonella 
Typhimurium emerged as a dominant cause of salmonellosis from 1970 onwards 
(Graham et al., 2000). Infection with multi-drug resistant NTS has been associated 
with an increased rate and duration of hospitalisation, a two-fold increased risk of 
death during a 2- year period after the infection, and an increased rate of invasive 
infection (Kariuki et al., 2005). 
1.4 (3-lactam Antibiotics 
fi-lactam antibiotics are the most frequently recommended class of antibiotics in 
the Standard Treatment Guideline (STG) and Essential Drugs List (EDL) devised 
by the South African Department of Health (National department of Health, 2006). 
Since the introduction of benzylpenicillin into clinical practice in 1940, several 
natural and synthetic (i-lactams have been described. Penicillin, penicillin 
derivatives, cephalosporins, cephamycins, carbapenems, monobactams and 
monocarbams are classified as R>-lactam antibiotics and are structurally related 
through the presence of a core p-lactam ring (Livermore and Williams, 1996; 
Williams, 1999). The physiological targets of p-lactam antibiotics are penicillin 
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binding proteins (PBPs) which are responsible for the synthesis and remodelling of 
the peptidoglycan which is a fundamental component of the cell wall of most 
bacteria and is of major importance in giving this layer its strength and rigidity. The 
amide group of the p-lactam ring is conformationally similar to the D-alanyl- D-
alanine bond of peptidoglycan pentapeptide. Inhibition of transpeptidation results in 
the formation of a non functional peptidoglycan, causing bacteriolysis (Livermore 
and Williams, 1996; Matagne et al., 1998). 
li-lactam resistance is becoming an increasing problem for clinicians worldwide, in 
both hospital and community settings. There are four major ways by which 
bacteria avoid the bactericidal effects of fi-lactams: 
• production of fi-lactamases 
(3-lactamases hydrolyse the active p-lactam ring. The destruction of R>-lactams by 
li-lactamases is the most common resistant mechanism in Gram-negative bacteria 
(Livermore, 1995). 
• active efflux of the antibiotic 
Efflux pumps expel the antibiotic before it can reach the target site hence 
inhibiting its action (Poole, 1994). 
• decrease in the permeability of the antibiotic 
The outer membrane in Gram-negative bacteria acts as an effective permeation 
barrier and retards the influx of antibiotic molecules into the bacterial cell. Altered 
porin profiles also retard the influx of the antibiotic (Nikaido and Vaara, 1985). 
• alterations of penicillin-binding proteins (PBPs) 
p-lactam antibiotics interfere with the biosynthesis of the bacterial cell wall by 
acting as analogues of the substrate for the PBPs that catalyse the synthesis of 
cross-linked peptidoglycan. A consequence of the alteration of PBPs is that the p-
lactam antibiotic cannot bind to it and hence cannot inhibit it (Waxman and 
Strominger, 1983). 
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1.5 (i-lactamase Mediated Resistance 
The first plasmid-encoded fi-lactamase that was able to destroy extended-
spectrum fi-lactam antibiotics was described in Germany in 1983. It was related to 
the production of the variant of the SHV-1 (sulfhydryl variable) enzyme, a broad 
spectrum penicillinase found in Klebsiella pneumoniae (Canton et ai, 2006). SHV-
1 differed from SHV-2 by replacement of glycine with serine at the 238 position. 
This mutation alone accounted for the extended spectrum properties of SHV-2. 
TEM-1 was first reported in 1965 from a patient in Greece, named Temoneira. This 
report was followed by the description in France of variants of TEM-1 and TEM-2 
enzymes with hydrolytic properties similar to SHV-1 derivatives. TEM-1 is able to 
hydrolyse ampicillin at a greater rate than carbenicillin, oxacillin, or cephalothin, 
and has negligible activity against extended-spectrum cephalosporins. It is inhibited 
by clavulanic acid. TEM-2 has the same hydrolytic profile as TEM-1, but differs 
from TEM-1 by having a more active native promoter and by a difference in 
isoelectric point (5.6 compared to 5.4) (Paterson and Bonomo, 2005). The TEM 
and SHV derivatives were named as extended spectrum (3-lactamases (ESBLs) in 
1989 (Canton et ai, 2006). According to the structural classification and the 
function scheme, these ESBLs are generally class A enzymes of the 2be group, 
arising as a result of a few amino acid substitutions, from the common TEM and 
SHV-1 p-lactamases (Bonnet et ai, 2000; Paterson and Bonomo, 2005). Changes 
at residue 164 are the most common changes observed in TEM variants. A 
reduction in the number of hydrogen bonds or the elimination of the electrostatic 
attraction weakens the linkage across the neck of the omega loop. This change 
allows more flexibility in the loop, which in turn opens more space for bulky R>-
lactam substituents, thus increasing resistance to these R>-lactams (Knox 1995). 
More than 150 TEM and over 90 SHV enzymes have been documented 
(http://www.lahey.org/Studies; Accessed 17 August 2008). ESBLs hydrolyse 
oxyimino-cephalosporins but are inhibited by clavulanic acid, are inactive against 
cephamycins and are often encoded by large plasmids that carry resistance 
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determinants to multiple antibiotics (Hopkins et al., 2008; Mhand etal., 1999). 
There are two major concerns with pathogens producing ESBLs, i.e., their capacity 
to cause therapeutic failures with cephalosporins and aztreonam when the isolate 
is susceptible in vitro, and their capacity for undetected, widespread dissemination 
(Hanson et al., 2002). 
Although reports of ESBLs associated with Salmonella spp. are not as many 
compared to those for other species in the family Enterobacteriaceae, the number 
of reported cases in this organism has been increasing (Mulvey et al., 2003). 
ESBLs in salmonellae in Africa were first described in 1988 (Cardinale et al., 2001). 
Salmonellae worldwide have been found to express a wide variety of ESBL- types 
including TEM, SHV, CTX-M, and PER enzymes. Additionally, Salmonella strains 
have been reported to produce plasmid-mediated AmpC-type ft-lactamases, the 
OXA- type class D (^.-lactamase, and the plasmid-mediated Class A 
carbapenemase (Kruger et al., 2004; Miriagou et al., 2003). 
A nosocomial outbreak of Salmonella infection in pediatric patients caused by 
Salmonella enterica serovar Isangi producing ESBLs was first reported from the 
Chris Hani Baragwanath Hospital, Johannesburg South Africa, in 2006 (Wadula et 
al., 2006). Fortunately strains harbouring metallo-enzymes such as VIM-types or 
IMP types have not yet been reported for Salmonella spp. In the early 1990s, 
nosocomial epidemics due to TEM-type ESBL-producing Salmonella spp. occurred 
in Algeria. During the period 1984 -1990 extended-spectrum cephalosporin 
resistant NTS producing SHV-type ESBLs were frequently isolated in pediatric 
units of Tunisian hospitals, while hospital outbreaks in Tunisia over the period 1995 
-2001 were caused by Salmonella strains producing SHV-2a. SHV-12- producing 
isolates of a novel serotype were isolated from human and poultry specimens in 
Senegal. Production of SHV-and TEM-type ESBLs is evident in NTS strains 
isolated in various European countries. There have been sporadic isolations of 
TEM-3, TEM-25- and SHV-2- producing strains in French hospitals. In some of 
these cases, the index strains had probably been introduced by patients 
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transferred from North African hospitals (Miriagou etal., 2004). An ESBL study of 
160 Salmonella spp. from 13 hospitals in South Africa conducted in 2004 reported 
that 15.6% of isolates produced TEM or SHV ESBLs (Kruger et a/., 2004). This 
study did not include the hospitals in Kwazulu-Natal. 
The CTX-M R-lactamases, a new family in class A ESBLs were characterized at 
the beginning of the 1990s with the first reports of the CTXM-1 enzyme from 
Germany (Bonnet etal., 2000). CTX-M enzymes share extensive sequence 
similarity with the chromosomal ^-lactamases of Klebsiella oxytoca. They efficiently 
hydrolyse many newer broad-spectrum oxyimino-fi-lactams including cefotaxime, 
ceftriaxone, and aztreonam and are readily inhibited by tazobactam and 
clavulanate (Tzouvelekis et ai, 2000). There are over 70 CTX-M genes identified 
(http://www.lahey.org/Studies/; Accessed 17 August 2008) which are divided into 
five phylogenetic groups, (CTX-M-1, -2, -8, -9 and -25) based on their amino acid 
sequences. Ceftazidime hydrolyzing CTX-M-type R> -lactamases such as CTX-M-
15, CTX-M-16 and CTX-M-19 were isolated in 2001 (Kimura etal., 2007). CTX-M-
type ESBLs display a level of resistance to cefotaxime and ceftriaxone significantly 
higher than to ceftazidime. The ceftazidime MICs for micro-organisms producing 
CTX-M-type ESBLs are usually within the susceptible range. Therefore the use of 
ceftazidime resistance as an indicator of ESBL production may miss ESBL-
producing bacteria in the clinical microbiology laboratory (Rotimi et ai, 2008). A 
number of CTX-M mutants with increased ceftazidimase activity have been 
described. The mutations in these variants occur in two of the structural elements 
that de-limit the ^.-lactam binding site, namely the terminal part of the B3 R>-strand 
and the omega loop. The Asp240Gly substitution in the terminal part of the B3 fi-
strand is responsible for increased flexibility of the fi-strand, rendering the active 
site more accessible to the bulkier ceftazidime molecule, while the substitutions in 
the omega loop (at position 167) apparently modify the mode of interaction of Q>-
lactams with the binding site (Rossolini et ai, 2008). 
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Most CTX-M li-lactamases reported in Africa (Kenya, Tanzania, Nigeria, Egypt) 
were from K. pneumoniae and Escerichia coli isolates. CTX-M-3 was found in a 
Salmonella isolate from the military hospital in Tunisia in 2001 and CTX-M-27 in 
isolates of S. enterica serotype Livingstone were the cause of a nosocomial 
outbreak in a neonatal ward in Tunisia in 2002 (Godet et al., 2005). CTX-M 
enzymes are now endemic in many countries with both nosocomial and community 
emergence and some ESBL studies have identified CTX-M enzymes as the most 
prevalent ESBL. The epidemiology of CTX-M-producing strains is quite complex. 
Outbreaks of CTX-M clonal strains have been reported throughout the world 
(Abassiefa/.,2008). 
PER-1, -2, and -3 comprise a highly clavulanate-sensitive family of ESBLs, with a 
different epidemiology from the TEM and SHV ESBLs. PER-1 was first identified in 
1991 in a Pseudomonas aeruginosa isolate from a Turkish patient. PER-1 
producing Salmonella Typhimurium strains were isolated from fatal nosocomial 
cases in 1992 at two hospitals in Istanbul (Vahaboglu et al., 1996). PER-1 has also 
been detected in France, Italy, Belgium and Korea in P. aeruginosa and 
Acinetobacter spp. isolates (Paterson and Bonomo, 2005). PER-2 was first 
detected in Salmonella Typhimurium in Argentina, and is now reported to be the 
second most prevalent ESBL in that country. Recently PER-3 was discovered in 
an isolate of Aeromonas punctata in France (Moland et al., 2008). 
The presence of AmpC li-lactamases in pathogens known not to have 
chromosomal ampC genes (like Salmonella) eventually led to the discovery of 
plasmid-borne AmpC enzymes such as ACT, ACC, DHA and CMY (Babic et al., 
2006). CMY (derived from Citrobacter Freundii) DHA (derived from Morganella 
morganii) and ACC-1 (derived from Hafnia alvei) have been found in Salmonella 
spp. (Miriagou et al., 2004). CMY-2 is the most prevalent of the plasmid-mediated 
AmpC enzymes and the most widely distributed geographically. CMY-type R>-
lactamases found in nosocomial enterobacteria, particularly in K. pneumoniae, and 
Salmonella spp. could have acquired the ampC gene from such microorganisms 
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(Miriagou et al., 2002). CMY-2 confers resistance to various extended spectrum 
cephalosporins, including ceftriaxone, which is the antibiotic of choice for invasive 
Salmonella infections in children. The movement of the ampC gene on to plasmids 
and transmission to other organisms is of major concern (Hanson et al., 2002). The 
expression of a plasmid-mediated CMY-2 fi-lactamase has been responsible for 
most ceftriaxone resistance in Salmonella spp. (Li et al., 2005). In Africa the first 
report of the CMY-2 gene in Salmonella was from an Algerian clinical isolate of S. 
enterica serotype Senftenberg in 1997 (Koeck et al., 1997), and in 2004 Kruger et 
al., reported the CMY-2 gene in Salmonella Typhimurium and S. enterica serotype 
Schwarzengrund from South Africa. 
Many organisms producing class C fi-lactamases may not be resistant to broad-
spectrum cephalosporins when conventional Clinical laboratory standard institute 
breakpoints are used. Yet, adverse clinical outcomes in patients with infections 
caused by organisms producing plasmid-mediated class C R>-lactamases have 
been reported when these patients were treated with cephalosporins. It is 
imperative that Salmonella spp. producing plasmid-mediated class C G-lactamases 
are detected and reported so that appropriate antimicrobial therapy and infection 
control measures can be initiated (Doi and Paterson, 2007). 
KPC, SME, NMC-A and IMI comprise a small group of class A R>-lactamases 
(functional group 2f) with potent carbapenemase activities (Miriagou et al., 2003). 
KPCs are capable of hydrolysing carbapenems, cephalosporins, and aztreonam, 
and they are inhibited by clavulanic acid and tazobactam (Cai et al., 2008). The 
only carbapenemase reported in Salmonella spp. is of the KPC-type. KPC-
producing K. pneumoniae strains have been found in hospitals in the USA and 
subsequently KPC-2 was found in a Salmonella serotype Cubana isolate also in a 
hospital in the USA. The emergence of Salmonella and K. pneumoniae strains 
producing plasmid-mediated KPC-type fi-lactamases in the USA further underlines 
the potential for exchange of resistance determinants between salmonellae and 
nosocomial enterobacteria (Miriagou et al., 2004). The KPC-type reportedly confers 
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resistance to all fi-lactams with MICs of imipenem and meropenem reported as 16 
and 8 mg/L respectively. These antibiotics are often the last therapeutic option 
used in cases of systemic infections in children due to ESBL-producing Salmonella 
(Arlet et a/., 2006). Other examples of non TEM, non SHV ESBLs such as GES, 
BES, SFO, TLA, IBC and VEB-1 have been described (Paterson and Bonomo, 
2005) but not reported in Salmonella spp. 
Historically the first characterised class D fi-lactamases were also referred to as 
oxacillinases because they commonly hydrolyse the isoxazolyl penicillin, oxacillin 
much faster than classical penicillins, i.e. benzylpenicillin. The designation OXA of 
the class D (i-lactamases, thus, refers to their preferred penicillin substrate. Most 
OXA-type fi-lactamases do not hydrolyse the extended-spectrum cephalosporins to 
a significant degree and are not regarded as ESBLs (Paterson and Bonomo, 
2005). The first identified isolate expressing an OXA-type carbapenemase was the 
OXA-23 producing A. baumanniifrom Scotland. The isolate was recovered in 1985, 
before or at the time when imipenem was approved for general use. There has not 
been many reports of the OXA fl-lactamase in Salmonella spp. and the first, OXA-
30, R>-lactamase was reported from an Australian pediatric Salmonella isolate in 
2002. The substrate specificities of the OXA-type carbapenemases are diverse, 
but generally the enzymes hydrolyse penicillins (benzylpenicillin, ampicillin, 
piperacillin and ticarcillin) and the narrow spectrum cephalosporins, cephalothin 
and cephaloridine efficiently, while the extended-spectrum ft-lactams, ceftazidime, 
cefotaxime and aztreonam are not or very poorly hydrolysed. Most of the OXA-type 
carbapenemases have low hydrolytic activities against imipenem and especially 
against meropenem. Generally, class D (i-lactamases are inhibited less efficiently 
by clavulanate than the majority of the other group 2 (l-lactamases to which the 
class D enzymes belong. All OXA-type carbapenemases are inhibited more 
efficiently by tazobactam than by clavulanate. Most of the OXA-type 
carbapenemases confer only reduced susceptibility to the carbapenems, but 
unless secondary resistance mechanisms, such as altered permeability, reduced 
affinity of PBPs for carbapenems or increased influx are involved, the clinical 
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detection of organisms producing these enzymes remains difficult. The 
chromosomal location of many of the OXA-type carbapenemase encoding genes 
has contributed to the slow spread of these genes (Rasmussen and Hoiby, 2006). 
1.6Quinolone Resistance 
The quinolones target bacterial type II topoisomerases, DNA gyrase and 
topoisomerase IV, which play important roles in DNA replication, chromosome 
segregation and DNA compaction. DNA gyrase is composed of two GyrA and two 
GyrB subunits and Topoisomerase IV is composed of two ParC and two ParE 
subunits (Okumura etal., 2008). Qnr-type plasmid-mediated quinolone resistance 
determinants belong to the pentapeptide-repeat family of proteins and protects 
DNA gyrase from quinolone inhibition. Three major groups of Qnr determinants, 
Qnr A, Qnr B, and QnrS have been identified worldwide in various members of the 
family Enterobacteriaceae (Wu et al., 2008). 
In Salmonella spp. as in other Enterobacteriaceae, a single point mutation in the 
quinolone resistance-determining region (QRDR) of the gyrA gene can mediate 
resistance to nalidixic acid and reduced susceptibility to fluoroquinolones such as 
ciprofloxacin. The most frequent point mutations in Salmonella spp. associated with 
resistance to quinolones occur in the gyrA gene resulting in substitutions at the 
Ser-83 position, often to Tyr, Phe, or Ala, and Asp-87 substitutions to Asn, Gly or 
Tyr. Substitutions in ParC are not as frequent as those found in GyrA. Changes in 
GyrB and ParE are rarely found in Salmonella spp. Although target gene 
mutations and efflux pumps are two mechanisms most commonly associated with 
fluoroquinolone resistance in bacteria, the additive or synergistic contribution of the 
two mechanisms in emerging fluoroquinolone resistance is not clear in Salmonella 
spp. There is evidence of strains with no mutation in the QRDR, but with a lack of 
the OmpF porin, which showed decreased susceptibility to fluoroquinolones 
(Fabregaefa/., 2008). 
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Resistance to nalidixic acid has been suggested to be an indicator of low level 
fluoroquinolone resistance (Rodriguez-Avial et ai, 2005). Although resistance to 
fluoroquinolones remains rare in Salmonella spp, reduced susceptibility is 
increasing worldwide and it has been suggested that fluoroquinolone-susceptible 
strains that test resistant to nalidixic acid may be associated with clinical failure or 
delayed response in fluoroquinolone-treated patients with extraintestinal 
salmonellosis (Cattoir etal., 2007; CLSI, 2008). Detection of Salmonella spp. 
isolates showing decreased susceptibility to fluoroquinolones has become 
important as a result of the increasing prevalence of these strains and their 
association with treatment failure (Aznar et ai, 2007). The increasing quinolone 
resistance in Salmonella spp. may have serious clinical consequences. Although 
antimicrobial treatment is commonly not needed in gastroenteritis caused by NTS, 
effective therapy is necessary in invasive infection. If such an infection is caused by 
a Salmonella strain with reduced fluoroquinolone susceptibility, treatment with a 
fluoroquinolone may not be a safe alternative (Hakenen et ai, 2006). 
A better understanding of the biology and epidemiology of resistant Salmonella 
isolates is needed to combat the emergence and spread, and to determine 
appropriate empirical therapy of infections caused by these organisms (Hanson et 
ai, 2002). Limited research of ft-lactamase mediated resistance on Salmonella 
spp. in South Africa motivated this study. 
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1.7. Aim 
To characterise resistance to R>-lactamase mediated resistance in putative ESBL 
positive Salmonella isolates collected at a tertiary hospital in KwaZulu-Natal. 
1.8 Objectives 
1.8.1 To verify the identity of the Salmonella bacterial strains by serotyping. 
1.8.2 To determine the antibiogram conferred by the organisms using the disc 
diffusion and minimum inhibitory concentration methods 
1.8.3 To verify the production of ESBLs using the E-Test. 
1.8.4 To determine the pi value of B-lactamases produced by isoelectric focusing. 
1.8.5 To detect the presence of B-lactamase genes by polymerase chain reaction. 
1.8.6 To identify the genes detected by DNA sequencing. 
Peripheral investigation 
1.8.7 To detect mutations in the quinolone resistance determining region and to 
search for the qnrA gene. 
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Abstract 
(J-Lactamase-mediated resistance was investigated in 59 putative extended-spectrum (^-lactamase (ESBL)-positive Salmonella spp. from 
the paediatric ward of a tertiary hospital in Durban, South Africa. Three Salmonella enterica serotype Isangi cultured from stool samples were 
multidrug resistant, with susceptibility only to meropenem, piperacillin/tazobactam and cefoxitin. Isoelectric focusing revealed p-lactamases 
with isoelectric points of pi 5.8, 6.8 and 7.2. Sequencing identified p-lactamases CTX-M-37 and TEM-l. To our knowledge, this is the first 
report of CTX-M-37 from S. enterica serotype Isangi in South Africa. 
© 2006 Published by Elsevier B.V. and the International Society of Chemotherapy. 
Keywords: Salmonella enterica serotype Isangi; CTX-M-37; Multidrug resistant 
1. Introduction 
Resistance to expanded-spectrum (3-lactam antibiotics in 
Enterobacteriaceae is often due to the presence of extended-
spectrum p-lactamases (ESBLs), which are plasmid-
mediated bacterial enzymes found in enteric Gram-negative 
organisms [1]. Although reports of ESBLs associated with 
Salmonella spp. are relatively rare compared with those for 
other species in the Enterobacteriaceae family, the number of 
reported cases in this organism has been increasing in recent 
years. Salmonella have been found to express a wide vari-
ety of ESBL types, including TEM, SHV, PER, OXA and 
CTX-M enzymes [2], 
CTX-M-type ^-lactamases are encoded by transferable 
plasmids and are found in various enterobacteria, mostly 
Salmonella typhimurium, Escherichia coli, Klebsiella pneu-
moniae and Proteus mirabilis [3]. This novel family of 
plasmid-mediated ESBLs has been classified in Ambler class 
* Corresponding author. Tel: +27 31 260 7413; fax: +27 31 260 7792. 
E-mail address: Govindenu@ukzn.ac.za (U. Govinden). 
A and in group 2be of the Bush, Jacoby and Medeiros clas-
sification [4]. 
CTX-M (i-lactamases were characterised at the beginning 
of the 1990s in the first reports of the MEN-1 (CTX-M-
1) p-lactamase. CTX-M-producing strains have since been 
reported over a wide geographic area [5]. In some coun-
tries, CTX-M-type enzymes are the most frequently isolated 
ESBLs from Gram-negative strains. CTX-M enzymes have 
been involved in several outbreaks, although isolation of 
CTX-M-producing strains remains sporadic [4]. Between 
January 2002 and March 2004, CTX-M-type ESBLs were 
reported for the first time in the UK, the USA, Italy, Turkey 
Bulgaria and Romania [6]. 
Approximately 40 CTX-M p-lactamases have been 
described and are divided into five major groups on the 
basis of similarities in amino acid sequences [7], Accord-
ing to Woodford et al., CTX-M-37 can be categorised 
into the CTX-M-1 group. In South Africa, CTX-M-2-
and CTX-M-3-type enzymes have been detected in K. 
pneumoniae [8]. In 2001, Kariuki et al. [9] reported a 
novel CTX-M-12, also from a K. pneumoniae isolate, 
in Kenya, but there has been no report of CTX-M-type 
0924-8579/$ - see front matter © 2006 Published by Elsevier B.V. and the International Society of Chemotherapy. 
doi:10.1016/j.ijantimicag.2006.05.028 
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enzymes in Salmonella spp. in South Africa. We report 
the first ccfotaximasc CTX-M-37 from a multidrug-resistant 
(MDR) Salmonella enterica serotype Isangi isolated in South 
Africa. 
2. Materials and methods 
2.1. Bacterial strains 
Salmonella isolates were cultured from stool samples 
received from the paediatric ward of a tertiary hospital in 
Durban in 2001. (3-Lactamase characterisation was under-
taken for 59 ESBL-positive Salmonella isolates received by 
the Antimicrobial Research Unit of the School of Pharmacy 
and Pharmacology at the University of KwaZulu-Natal. The 
identity of the strains as Salmonella spp. was confirmed 
using the API 20E system (bioMerieux sa, Marcy l'Etoile, 
France). Serotyping of the isolates was performed by the 
hospital laboratory using the slide agglutination method on 
the basis of lipopolysaccharide (O) and flagellar (H) antigens 
and commercially available antisera, according to the 
Kauffman-White scheme for Salmonella serotyping [10]. 
Escherichia coli NCTC 50192 served as a source of plasmid 
markers. 
2.2. Susceptibility testing and ESBL detection 
Susceptibility testing was undertaken using the National 
Committee for Clinical Laboratory Standards disk diffu-
sion test. Minimum inhibitory concentrations (MICs) were 
extrapolated by the BIOMIC® automated reading system and 
software (Giles Scientific, New York, NY), using the follow-
ing antibiotics: ampicillin, amoxicillin/clavulanic acid, ampi-
cillin/sulbactam, piperacillin, carbenicillin, ticarcillin, cef-
tazidime, cefalothin, ceftriaxone, cefepime, cefuroxime (par-
enteral), cefotaxime, cefoxitin, meropenem, aztreonam and 
piperacillin/tazobactam. ESBL production was confirmed by 
the Etest method according to the manufacturer's guidelines 
(AB Biodisk, Solna, Sweden). 
2.3. Plasmid analysis 
Plasmid DNA was extracted by the method of Kado and 
Liu [11]. Samples were analysed by electrophoresis in l x 
TBE buffer at 120 V for 1 h on 0.8% agarose gels. Plasmid 
size was estimated by comparison with plasmids from E. coli 
NCTC 50192. 
2.4. Isoelectric focusing (IEE) of ^-lactamases 
Bacterial cells were broken by the freeze-thaw method 
[ 12] and IEF of crude extracts was performed on polyacry-
lamide gels containing ampholines with an isoelectric point 
range of pi 3.5-9.5. (3-Lactamase bands were visualised with 
nitrocefin (Oxoid Ltd., Basingstoke, UK). 
2.5. PCR detection ofblaj-EM, blasHV and blacrx-M 
genes 
Bacterial DNA was prepared by suspending a few fresh 
colonies from an overnight Mueller-Hinton agar culture 
in 50 |xL of sterile distilled water and heating the cells at 
95 °C for 5 min. Polymerase chain reaction (PCR) ampli-
fication was then performed in a Gene Amp PCR System 
(Applied Biosystems, Foster City, CA). All the primers used 
are described in Table 1. PCR for amplification of WOTEM 
and blasHV genes was carried out as described by Essack 
et al. [13]. The amplification mixture for the detection of 
blacrx-M genes was prepared in a final volume of 50 |xL con-
taining 2 |xL of the template DNA, lOpmol of primer, 25 |xL 
of master mix (Applied Biosystems) and water. The PCR pro-
gramme consisted of an initial denaturation step at 94 °C for 
3 min, followed by 25 cycles of DNA denaturation at 94 °C 
for 30 s, primer annealing at 54 °C for 1 min and primer exten-
sion at 72 °C for 2 min and a final extension step at 72 °C for 
7 min. Aliquots (5 |j,L) of PCR product were analysed by 
gel electrophoresis with 2% agarose. Negative controls com-
prised PCR mixtures with the addition of water instead of 
template DNA. Gels were stained with ethidium bromide at 
10 p.g/mL and photographed with ultraviolet illumination. A 
1000 bp DNA ladder (Fermentas, Lithuania; purchased from 
Inqaba Biotechnical Industries) was used as a size marker. 
2.6. Sequencing 
The primers used for DNA sequencing are shown in 
Table 1. Sequencing of the amplified products was performed 
with the BigDye version 3.1 dye terminator cycle sequencer 
from Applied Biosystems. 
2.7. Nucleotide sequence accession number 
Sequences were analysed using the BLAST 2.0 (Basic 
Local Alignment Search Tool) software available on the web-
site of the National Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/BLAST/; accessed 6 Septem-
ber 2005). The nucleotide and amino acid sequences of 
CTX-M-37 have been deposited in GenBank and assigned 
accession number AY935578. 
3. Results 
Serotyping confirmed isolates 509, 541 and 640 to be S. 
enterica serotype Isangi. The MIC data are shown in Table 2. 
All three isolates were ESBL-positive. Isolates 509, 541 
and 640 exhibited considerable resistance to carbenicillin, 
piperacillin, ticarcillin, cefotaxime, ceftazidime, cefalothin, 
ceftriaxone, cefuroxime and cefepime. Resistance was also 
noted with aztreonam, amoxicillin/clavulanic acid (MICs > 
64|jLg/mL), ampicillin and ampicillin/sulbactam (MIC> 
48 pig/mL). Susceptibility to piperacillin/tazobactam, cefox-
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Table 1 
Primers used in this study 
Primer Function Sequence (5'-3') Nucleotide positions 
TEM 1 (F) 
TEM 2 (R) 
TEM 3 (R) 
TEM 4 (R) 
SHV 1 (F) 
SHV2(R) 






































F, forward primer; R, reverse primer; Amp, amplification; Seq, sequencing. 
Table 2 







































































itin and meropenem was exhibited by all three isolates. Plas-
mids of 63.8 kb and 148.5 kb were detected. P-Lactamases 
with pi values of 5.8, 6.8 and 7.2 were observed for isolates 
509 and 640, whilst isolate 541 contained only two isoelectric 
points at pi 5.8 and 7.2. PCR amplification revealed that all 
three isolates harboured blajEM and blacrx-M ^-lactamase 
genes. No PCR products were obtained with primers specific 
for WasHV genes. Sequence data for each amplicon identi-
fied the genes as WaiEM-i and Wacrx-M-37- The pi of 5.8 
can be ascribed to the TEM-1 (3-lactamase and the pi of 7.2 
could account for the CTX-M-37 (3-lactamase. The pi of 6.8, 
although suggestive of a TEM-type fj-lactamase, needs fur-
ther investigation. 
4. Discussion 
Resistance of Salmonella to expanded-spectrum cephalos-
porin antibiotics is of significant public health impor-
tance. Since 2000, the Enteric Diseases Reference Unit 
of the National Institute for Communicable Diseases 
in South Africa has noted increasing numbers of non-
typhoidal Salmonella isolates, particularly S. enterica 
serotype Typhimurium and S. enterica serotype Isangi, 
with positive screening tests for ESBLs [2]. An outbreak 
of typhoid in KwaZulu-Natal owing to MDR resistant S. 
typhimurium was first reported in South Africa in 1992. 
There was a high mortality rate during this outbreak 
and only two children were successfully treated with the 
third-generation cephalosporins ceftriaxone and cefotaxime 
[14]. 
Isolates 509, 541 and 640 were ESBL-positive and 
resistant to multiple antibiotics, being susceptible only to 
meropenem, cefoxitin and piperacillin/tazobactam. Suscepti-
bility to piperacillin/tazobactam is consistent with most class 
A ESBLs, as CTX-M enzymes exhibit greater susceptibil-
ities to p-lactamase inhibitors [7]. The MIC of cefotaxime 
(>256 |i.g/mL) in all three isolates was higher than that for cef-
tazidime (>128 |a.g/mL). In contrast to TEM- and SHV-type 
cefotaxime-hydrolysing ESBLs, CTX-M enzymes are much 
more active against cefotaxime than against ceftazidime. The 
amino acid residues critical for their extended spectrum of 
activity are distinct from those of TEM- and SHV-1-derived 
ESBLs [2]. 
Amino acid substitutions in TEM- and SHV-type p~ 
lactamases are known to result in the development of their 
extended spectrum of activity. In the case of SHV-2, the 
G238S substitution results in enlargement of the omega loop, 
giving larger molecule substrates such as the oxyimino-
cephalosporins access to the active site. Similar events have 
occurred for the CTX-M enzymes, most notably amino acid 
substitution D240G in CTX-M-15, CTX-M-16, CTX-M-25, 
CTX-M-27, CTX-M-28, CTX-M-29, CTX-M-30 and CTX-
M-32, which results in greater hydrolysis of ceftazidime 
[6,15]. Poirel et al. [16] have recently reported that CTX-
M-19, a Prol67Ser mutant, could hydrolyse ceftazidime effi-
ciently. Although the MIC of ceftazidime for isolates 509, 
541 and 640 is > 128 |j,g/mL, there was no amino acid substi-
tution detected at Asp240 or Pro 167. However, all character-
istic substitutions assumed to be implicated in cephalosporin 
hydrolysis such as Cys-69, Ala-205, Ser-237, Thr-244 and 
Arg-276 in the CTX-M-type P-lactamases [17] are present 
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in CTX-M-37, which could contribute to the high MIC of 
ceftazidime and other cephalosporins. 
The Asnl04, Asnl32, Ser237 and Asp240 residues 
present in all three isolates establish hydrogen bonds with the 
amide and aminothiazole groups of the acylamide cefotaxime 
chain. This unusual acyl intermediate of CTX-M enzymes in 
complex with cefotaxime may therefore be involved in the 
activities of the oxymino-cephalosporinases by fixing cefo-
taxime tightly in the binding site [7]. 
The intensive use of broad-spectrum cephalosporins such 
as cefotaxime could account for the emergence of the CTX-M 
enzyme. Mutants of CTX-M enzymes harbouring improved 
catalytic efficacies against ceftazidime have recently been 
observed, suggesting that the enzymes are evolving as a result 
of ceftazidime selection pressure [6]. The continued use of 
ceftazidime in South Africa could contribute to the evolution-
ary potential of the CTX-M enzyme. Screening by molecular 
methods will be necessary to determine the prevalence of 
CTX-M-producing strains in our hospitals. 
5. Conclusion 
Although the first CTX-M enzymes were characterised 
from strains isolated in 1989, their significant expansion 
started only in 1995 [7], CTX-M-37 (GenBank acces-
sion number AY649755) was first reported in 2004 in 
Mangolia from an Enterobacter cloacae clinical isolate 
(http://www.ncbi.nlm.nih.gov; accessed 6 September 2005). 
To our knowledge, this is the first report of CTX-M-37 from 
S. enterica serotype Isangi in South Africa. 
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The CTX-M- type extended spectrum p-lactamases (ESBLs) that preferentially hydrolyze cefotaxime are 
emerging globally and comprise of more than 50 enzymes. The emergence of novel CTX-M p-
lactamases in several countries is noted as opposed to the transfer of established CTX-M genes from 
one country to another, suggestive of a cte novo dissemination of CTX-M genes. 
Key words: CTX-M p-lactamase, geographic evolution, epidemiology. 
INTRODUCTION 
Extended spectrum p-lactamases (ESBLs) are molecular 
class A or D p-lactamases , which are able to hydrolyze 
oxymino cephalosporins at a rate equal to or higher than 
10% of that for benzylpenicillin, have an active-site se-
rine, and are generally inhibited by p-lactamase inhibitors 
such as clavulanic acid, sulbactam or tazobactam. 
ESBLs are mostly encoded by large plasmids (up to 100 
kb and even more) that are transferable from strain to 
strain and between bacterial species (Sturenburg and 
Mack, 2003). Hence, ESBLs are an increasingly impor-
tant cause of resistance to multiple p-lactam drugs in 
gram-negative bacteria (Livermore and Hawkey, 2005) 
'Classical' ESBLs such as TEM (Temoniera) and SHV 
(sulfhydryl variable) have evolved from the widespread 
plasmid encoded enzyme families (Sturenburg and Mack, 
2003). 
Within a few years after its first isolation from an 
Escherichia coli isolate from a Greek patient named 
Temoniera, the TEM-1 p-lactamase was found worldwide 
and production of this enzyme is now the most commonly 
encountered mechanism of resistance to the p-lactam 
group of drugs in gram-negative bacilli. The first TEM 
variant with increased activity against extended-spectrum 
cephalosporins was TEM-3, which was reported in 1987. 
Since then there has been a rapid increase in the number 
"Corresponding author. E-mail: Govindenu@ukzn.ac.za. Tel: + 
2731-2608251; Fax + 2731-2607792. 
and variety of extended-spectrum TEM variants 
(Sturenburg and Mack, 2003). More than 150 TEM 
derivatives have currently been documented (http:// 
www.lahey.org/Studies; last assessed 1 December 
2006). 
The SHV family of p-lactamases appears to have been 
derived from Klebsiella spp. SHV-1, is universally found 
in Klebsiella pneumoniae. In 1983, three strains of K. 
pneumoniae and one strain of Serratia marcescens iso-
lated in West Germany were able to transfer resistance to 
cefotaxime as well as to the newer cephalosporins. This 
new plasmidic p-lactamase, called SHV-2, was derived 
from a point mutation in SHV-1. This mutation, at position 
238 from glycine to serine resulted in an enhanced 
affinity of the SHV-1 p-lactamase for oxyimino cephalo-
sporins, with a significant rise in the MIC of cefotaxime 
and a more limited rise in the MIC of ceftazidime. 
Subsequently, a number of ESBL variants containing 
amino acid changes have been reported (Sturenburg and 
Mack, 2003). There are now over 90 SHV-type enzymes 
(http://www.lahey.org/Studies; last accessed 1 December 
2006). 
In 1989, non-TEM, non-SHV, ESBL-producing bacteria 
expressing a higher level of resistance to cefotaxime than 
to ceftazidime was described in E. coli isolates from 
Germany. Owing to the high activity against cefotaxime, 
these new members of the ESBL family were named 
CTX-M p-lactamases (Rasmussen and Hoiby, 2004). The 
CTX-M family comprises more than 50 enzymes from 
various countries as described in Table 1 and can be 
096841 
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subclassified by amino acid sequence similarities. A 
phylogenic study reveals five major groups of CTX-M 
enzymes with the members of each group sharing >94% 
identity, whereas 2 90 % identity is observed between the 
members belonging to distinct groups (Bonnet, 2004). 
The five major groups are clusters of CTX-M-1,-2,-8, -9 
and -25 (http://www.lahey.org/Studies/, last accessed 1 
December 2006). 
As a group, the CTX-M-type 3-lactamases are closest 
in amino acid identity to the chromosomal cephalo-
sporinases of Kluyvera georgiana, Kluyvera cryorescens, 
and Kluyvera ascorbata (Paterson et al., 2003). The 
natural CTX-M (3-lactamases of K. ascorbata, designated 
KLUA (3-lactamases, are clustered in the CTX-M-2 group. 
The KLUA-2 (3-lactamase of K. ascorbata strain IP15.79 
is identical to the CTX-M-5 (3-lactamase characterized in 
a Salmonella enterica serovar Typhimurium strain. The 
natural 3-lactamase KLUG-1 of K. georgiana strain 
CUETM4246-74 clusters with the CTX-M-8 (3-lactamase. 
These relationships of amino acid sequences between 
the natural (3-lactamase of Kluyvera strains and the CTX-
M (3-lactamase suggest that the natural 3-lactamases of 
K. ascorbata and K. georgiana are the progenitors of the 
CTX-M-2 and CTX-M-8 groups, respectively. A natural 
CTX-M (3-lactamase has also been characterized from K. 
cryocrescens. This 3-lactamase, designated KLUC-1, 
shares only 85 to 86% identity with the most closely 
related (3-lactamases, which belong to the 3-lactamases 
of the CTX-M-1 group, although an enzyme identitical to 
CTX-M-3 was isolated from a strain of K. ascorbata. The 
CTX-M-9 group is related to enzymes from Kluyvera spp. 
isolated from Guyana, which were identical to CTX-M-14 
(Bonnet, 2004; Pitout et al., 2005a). 
Different genetic elements are associated with bla 
CTX-M genes. ISECPMike insertion sequences are most 
frequently reported. This insertion sequence element has 
been found to be associated with four out of the five bla 
CTX-M clusters (CTX-M-1 ,-2,-9 and -25 clusters) (Larti-
gue et al., 2006). Many CTX-M genes are located near or 
within transposons, or within mobile gene cassettes, 
which could permit rapid dissemination, thus CTX-M-
producing strains have a growing distribution and preva-
lence. South America, Mediterranean and Eastern Euro-
pean countries as well as East Asia account for most 
reported isolates (Hopkins et al., 2006). 
EPIDEMIOLOGY OF CTX-M B-LACTAMASES 
America 
In Argentina, a nationwide replacement of cefotaxime 
with ceftriaxone in 1990 co-incided with severe infections, 
diagnosed with meningitis, septicaemia, and enteritis. 
The infections emerged in August 1990 and were caused 
by multiresistant strains of Salmonella typhimurium which 
were resistant to cefotaxime but susceptible to ceftazi-
dime, owing to the production of CTX-M-2 (Rasmussen 
and Hoiby, 2004). ESBLs were assessed by Patterson et 
al. (2003) in a collection of 455 isolates of K. pneumoniae 
from 12 hospitals in 7 countries between 1996 and 1997. 
Of the 18 ESBL positive isolates from Argentina, 11 
produced the CTX-M-2 type (3-lactamase. An ESBL study 
of 427 enterobacterial strains identified CTX-M-2 in 19 
isolates and CTX-M-31 (a variant of CTX-M-2) in 2 
isolates (Quinteros et al., 2003). An ESBL study of 18 
Enterobacteriacae strains collected in 1996 and 1997 
from hospitals in Brazil identified CTX-M-8 in Citrobacter 
amalonaticus and CTX-M-2 in Proteus mirabilis (Bonnet 
et al., 2000). CTX-M-9 and CTX-M-16 (differing from 
CTX-M-9 by only 1 amino acid substitution) were 
observed in 2 of 3 E. coli strains from hospitals in Brazil 
in 1996 (Bonnet et al., 2001). During the period 2000 to 
2002 CTX-M-14 3-lactamases were responsible for a 
community-wide outbreak in the Calgary Health Region 
of Canada (Pitout et al., 2005b). In 2004 Abdalhamid et 
al. reported the presence of CTX-M-30 in Citrobacter 
freundii from 4 different patients in Canada. In 2004 in 
Colombia, 7 K. pneumoniae isolates that were collected 
from three different hospitals were positive for the CTX-
M-1 group and CTX-M-12 was identified in 1 isolate 
(Villegas et al., 2004). In 2004 Liebana et al. reported 
CTX-M-15 that was characterized in 2002 from a 
paediatric patient with a S. enterica serotype Infantis 
infection in Honduras. 
Asia 
In Japan in 1986, Matsumoto et al. discovered a non-
TEM, non-SHV ESBL, in a cefotaxime-resistant E. coli 
strain isolated from the faecal flora of a laboratory dog 
which was used for pharmacokinetic studies of 3-lactam 
antibiotics (Bonnet, 2004). A few years later, Ishii et al. 
(1995) reported on a CTX-M-1-related enzyme, desig-
nated Toho-1 (CTX-M-44), which was produced by a 
cefotaxime-resistant E. coli strain isolated from the urine 
of a patient in 1993 in Japan. In 1998, Ma et al. also 
reported a cefotaxime resistant E. coli isolate containing 
Toho-2 (CTX-M-45). Surveys of ESBL-producing Entero-
bacteriaceae in Japan showed that the CTX-M-2 and 
CTX-M-3 enzymes predominate. At least three outbreaks 
involving CTX-M enzymes have occurred in Japan, 
implicating clonal E. coli spread (Bonnet, 2004). The 
molecular types of CTX-M- 3-lactamases in Japan were 
investigated in 1397 gram-negative bacilli collected bet-
ween 2001 and 2003. 317 isolates were positive for CTX-
M-type 3-lactamases. The investigation revealed that 
gram-negative nosocomial bacilli producing the CTX-M-1, 
-2 or -9 group of enzymes had already been dispersed in 
various clinical settings in Japan, although strains that 
produce TEM-or SHV-derived ESBLs are infrequently 
found (Shibata et al., 2006). 
The first cefotaximase-producing (CTX-M-3) in a non-
clinical S. enterica serovar Senftenberg in Japan was 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































•Amino acid sequences of CTX-M-14 and CTX-M-18 are identical. 
"Data adapted from Lahey (http://www.lahey.org/Studies/ ; last accessed 1 December 2006) and Genbank (http://www.ncbi.nlm.nih.; last 
accessed 1 December 2006). 
isolates of various Salmonella serovars were screened 
for ESBL production. Only 1 strain of S. enterica serovar 
Senftenberg was isolated from river water in Hiroshima in 
1999 and displayed an ESBL phenotype (Ahmed et al., 
2004). 
In China, CTX-M-3,-9,-13 and-14 type enzymes have 
been reported from E coli, K. pneumoniae, and 
Enterobacter cloacae strains. At the Huashan Hospital in 
China, CTX-M enzymes were the second most frequent 
ESBLs after SHV enzymes in K. pneumoniae (8 of 80) 
and E coli (13 of 58) strains in 1999 (Bonnet, 2004). 
Molecular characterization of 57 ESBL strains in a study 
in 2005 in China revealed that the majority of the strains 
(94.7%) were CTX-M type, with a predominance of CTX-
M-14 and -3 types (Pottumarthy et al., 2005). An ESBL 
study in the Anhui province in China identified 54 CTX-M 
positive E. coli and K. pneumoniae isolates. The isolates 
contained CTX-M-14 type B-lactamase with one to three 
point mutations occurring in eight isolates. The enzymes 
were designated CTX-M-46,-47,-48,-49 and -50 (Li and 
Li, 2005; http://www.lahey.org/Studies/; last accessed 1 
December 2006). 
In Taiwan, at the National Cheng Kung University 
Hospital, a study of ESBL-producing K. pneumoniae 
strains conducted in 1999 revealed predominance 
(57.9%) of unrelated CTX-M-3-producing strains. Another 
survey performed in 24 hospitals between 1998 and 2000 
showed inter- and intra-hospital clonal dissemination of 
CTX-M-3-producing (28 of 50) and CTX-M-14-producing 
(22 of 50) K. pneumoniae strains (Bonnet, 2004). In 2003 
Paterson et al., reported the presence of a CTX-M-3 type 
3-lactamase in a single K. pneumoniae isolate from a 
hospital in Taiwan. During September 2000 to December 
2001 88 ESBL Enterobacteriaceae isolates from the 
Chang Gung children's hospital in Taiwan produced CTX-
M-3 in 52 isolates. This was the most prevalent ESBL. 
CTX-M-3 was also the most common type of ESBL 
produced by E. coli and K. pneumoniae (Wu et al., 2003). 
Wu et al. also identified CTX-M -3 in 22 out of 34 S. 
marcescens clinical isolates from a medical centre in 
Taiwan. A study reported in 2006 from seven medical 
centres in Taiwan, described CTX-M-type 6-lactamases 
as one of the most prevalent ESBLs. CTX-M- 3, -9, -14, -
15, -17, -19, and -38 were identified in this study (Yan et 
al., 2006). 
In different parts of Korea, the CTX-M-14 enzyme was 
also observed in K. pneumoniae and E coli strains 
between 1995 and 1996 and in a Shigella sonnei strain 
isolated during an outbreak of gastroenteritis in 2000 
(Bonnet, 2004). CTX-M-3, -9, -14 and -15 were detected 
in 41 out of 603 isolates of Enterobacteriaceae collected 
in 2003 from three university hospitals in Korea (Kim, 
2005). In 2004 a nosocomial outbreak of paediatric gas-
troenteritis in Korea was caused by CTX-M-14 type ESBL 
producing strains of S. enterica serovar London. The 
isolates had pulsed-field gel electrophoresis patterns 
identical to those of the previously isolated antimicrobial 
susceptible strains from community-acquired gastroen-
teritis, suggesting the susceptible clone acquired the 
resistance (Yong et al., 2005). A novel ceftazidime-
hydrolyzing CTX-M mutant, CTX-M-54, produced by a K. 
pneumoniae isolate in Korea was reported by Bae et al. 
(2006). CTX-M-14 and a variant designated CTX-M-17 
have commonly been observed in E coli and K. pneu-
moniae strains since 1996 in Ho Chi Minh City, Vietnam 
(Bonnet, 2004). 
CTX-M-37 (Genbank accession number AY 649755) 
was first reported in 2004 in Mongolia from E cloacae cli-
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nical isolate (http://www.ncbi.nlm.nih. last accessed 1 
December 2006). Five Enterobacteriaceae strains 
producing CTX-M-2, -9, -11 and -15 were reported in 
2004 in Singapore (Koh et al., 2004). In India, CTX-M-15 
was reported in 2001 from six non-clonally related 
members of the family Enterobacteriaceae (Karim et al., 
2001). 
Europe and Middle East 
At a Hospital in Warsaw, Poland, during a 4-month period 
between 1996 and 1997, the majority (27 of 35) of ESBL-
producing strains of the family Enterobacteriaceae 
expressed a CTX-M-3-like enzyme. A 4-month survey 
performed in seven Polish hospitals in 1998 revealed the 
predominance of an SHV -ESBL (60.4%) and similar 
frequencies of TEM and CTX-M ESBLs (20.8 and 18.8%, 
respectively). A wider survey undertaken between 1998 
and 2000 in 15 hospitals in 10 different cities of Poland 
revealed the countrywide dissemination of the CTX-M-3 
enzyme. This great inter- and intra-hospital outbreak was 
due to the clonal spread of a few strains and more 
particularly to the dissemination of a CTX-M-3-encoding 
plasmid in E. coli, K. pneumoniae, Klebsiella oxytoca, C. 
freundii, S. marcescens, E. cloacae, and Morganella mor-
ganii. S. enterica serovar Typhimurium strains harboring 
a distinct CTX-M-3-encoding plasmid have also been 
reported. CTX-M-15, a variant of CTX-M-3 previously 
described in India, has also been observed in Poland as 
well as in Bulgaria, Romania, and Turkey (Bonnet, 2004). 
The CTX-M-2 type 8-lactamase in a single K. pneumo-
niae isolate from a hospital in Turkey was reported by 
Paterson et al. (2003). A large outbreak of Salmonella 
gastroenteritis that involved 4000 children in Latvia in 
1990 was still ongoing when reported in 1998. The majo-
rity of cases were associated with S. typhimurium strains 
producing CTX-M (3-lactamases. CTX-M-5 was found in 
one of these strains (Tzouvelekis, 2000). 
A small outbreak involving CTX-M-4-producing S. enfe-
rica serovar Typhimurium strains occurred in Russia in 
1996. The strain involved has been observed in Greece 
and Hungary. Clonal spread of CTX-M-producing S. 
enterica serovar Typhimurium strains in at least three 
European countries was detected. The enzymes implica-
ted (CTX-M-4,-6, and -7) were variants of CTX-M-2, like 
the CTX-M-5 observed in the Latvian strain. CTX-M-3-
producing E. coli strains unrelated to those reported in 
Poland were also isolated in Greece (Bonnet, 2004). An 
outbreak of K. pneumoniae producing CTX-M-3-type (3-
lactamases occurred in Novosibirsk in the period 1997 to 
1998. The outbreak was caused by a proliferation of 2 
major clones. Between 1997 and 1998, nosocomial isola-
tes of E. coli and K. pneumoniae were collected from 28 
Russian hospitals with CTX-M-1 (3-lactamase being the 
most prevalent (Rasmussen and Hoiby, 2004). 
The CTX-M enzyme was first characterized in Western 
Europe in two E. coli strains isolated in 1989 in Germany 
and in France from an Italian patient. In 2004 Sturenburg 
et al. reported the presence of CTX-M-23 from E. coli and 
K. pneumoniae strains which were isolated from a 46-
year-old man in Germany during treatment of postopera-
tive peritonitis with ceftazidime (Sturenburg et al., 2004). 
Since 1989, 11 different CTX-M enzymes have been 
reported in France from sporadic E coli (CTX-M-1,-2,-9,-
14, -18, -19, - 21 and -27), P. mirabilis (CTX-M-1 ,-2 and -
20), and E. cloacae (CTX-M-1 and -3) isolates (Bonnet, 
2004). However, in 2006 Eckert et al. (2006) reported 7 
CTX-M-type (3-lactamases (CTX-M-1, -2, -3, -9, -14, -15 
and -24) among 28 strains of Enterobacteriaceae that 
were collected from five different hospitals in Paris, Fran-
ce. The emergence and spread of three clonally related 
virulent isolates of CTX-M-15-producing E. coli in a 
French geriatric hospital was reported in 2004 (Leflon-
Guibout et al., 2004). 
Paterson et al. (2003) identified 1 CTX-M-2 type 13-
lactamase from a K. pneumoniae isolate in Belgium in 
2003. Three hundred and sixty Enterobacteriaceae and 
non fermenting gram-negative bacilli isolated during one 
week in 2004 at 5 hospitals in Netherlands were evalua-
ted for the presence of ESBLs. CTX-M-1 ,-2,-9 and -15 
were found among 18 isolates (Naiemi et al., 2006). At a 
Hospital in Madrid, Spain, the investigation of ESBL-
producing Enterobacter strains from 1989 to 2000 sho-
wed the persistence of CTX-M-10 over a 12-year period in 
unrelated isolates. At a Hospital in Barcelona, Spain, the 
majority (6 out of 10) of ESBL-producing Enterobac-
teriaceae isolated between 1994 and 1996 produced 
CTX-M-9 enzymes. In the same area, a CTX-M-9-like 
enzyme was also observed in three S. enterica serovar 
Virchow strains isolated between 1997 and 1998. In the 
northwest area of Spain, 50% of ESBL-producing strains 
of the family Enterobacteriaceae isolated in 2001 produ-
ced the CTX-M-14 enzyme (Bonnet, 2004). Four S. 
enterica serovar Virchow strains resistant to broad-spec-
trum cephalosporins were isolated from patients with 
gastroenteritis in 1997 and 1998 in Murcia and Barce-
lona, Spain. The isolates expressed a CTX-M-9 type (3-
lactamase (Simarro et al., 2000). In 2003 Pagani et al. 
reported the detection of CTX-M-1,-2 and -15 in 12 out of 
232 ESBL producers from a Spanish hospital in Northern 
Italy. The most prevalent CTX-M ESBLs [CTX-M-9 
(27.3%) and CTX-M-14 (20.5%)] were found in E. coli, in 
a nationwide study of E. coli (n = 170) and K. pneumo-
niae (n = 70) producing ESBLs in Spanish hospitals in 
2005, whilst CTX-M-10 was found in only 3 K. pneumo-
niae isolates (Hernandez et al., 2005). In 2005 a large 
outbreak was caused by CTX-M-1- producing multiresis-
tant K. pneumoniae in a Spanish intensive care unit (51 
patients) (Mena et al., 2006). The prevalence and types 
of genes encoding ESBLs in 642 clinical isolates of 
Enterobacteriaceae, Pseudomonas aeruginosa, and 
Acinetobacter spp. were assessed in Bolivia in 2004. 
106 out of the 150 putative ESBL producing isolates con-
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tained CTX-M-2, and 32 isolates contained CTX-M-43 
(Celenza et al., 2006). A study in 2005 reported the 
detection of CTX-M-1-producing clinical isolates of C. 
amalonaticus and M. morgan! from an area of Northern 
Italy where CTX-M producers were found to be 
widespread in E. coli. This study showed that the CTX-M-
1 [3-lactamase was possibly acquired by these unusual 
hosts in vivo, after co-infection with E. coli strains 
carrying conjugative plasmids bearing the bla CTX-M-1 
gene (Mugnaioloi et al., 2005). The first description of 
CTX-M-15 producing K. pneumoniae in Portugal was 
reported in 2005 (Conceicao et al., 2005). 
The first outbreak caused by K. pneumoniae producing 
CTX-M-26 was recorded in Birmingham England in 2001 
(Livermore and Hawkey, 2005). The United Kingdom 
(UK) has experienced a sudden rise in ESBL rates, 
largely due to the appearance and spread of E. coli 
producing CTX-M-15 type (3-lactamase. The first signifi-
cant outbreak of CTX-M producers in the UK occurred in 
2001 involving K. pneumoniae with CTX-M-26 at one site, 
but by 2003, cloned and diverse E. coli with CTX-M-15 
were widespread (Livermore and Hawkey, 2005). CTX-
M-40 from an E. coli strain was reported in 2006 from the 
UK. The strain had been isolated from an immunocom-
promised hospital patient in 1998, which had initially been 
treated with piperacillin/tazobacam and netilmicin but did 
not respond clinically until piperacillin/tazobacam was 
replaced with meropenem (Hopkins et al., 2006). 
Among 149 ESBL producing Enterobacteriaceae isola-
tes collected from patients in Austria from 1998 to 2004, 
38 E coli isolates and 11 Klebsiella spp. were CTX-M 
producers. The proportion of CTX-M producers (group 1 
and group 9) among all ESBL positive isolates rose from 
0% in 1998 to 58% in 2004. One E. coli isolate was 
identical to the UK epidemic CTX-M-15- producing strain, 
although no epidemiological link with the UK was appa-
rent (Eisner et al., 2006). Between January 2001 and 
April 2005 a large collection of human and animal isola-
tes of Salmonella spp. was collected in Ireland to deter-
mine the prevalence of ESBLs. Seven ESBL producing 
isolates were detected. Two isolates produced CTX-M-15 
and one isolate produced CTX-M-14 (Morris et al., 2006). 
In 2005 a study was reported on the extent of ESBL 
producing Enterobacteriaceae at hospital and community 
level in Lebanon. Out of a total of 72 strains, 83% 
expressed the CTX-M-15 (3-lactamase (Moubareck et al., 
2005). The molecular epidemiology of ESBL producing E. 
coli isolates (n = 20) was investigated in a tertiary care-
teaching hospital in Tel Aviv, Israel in 2005. 15 isolates 
exhibited CTX-M-2, and 3 isolates exhibited a new CTX-
M-39 (3-lactamase (Chmelnitsky et al., 2005). ESBL 
production was demonstrated in five independent, multi-
drug-resistant isolates of enteroaggregative E coli 
(EAEC) from the United Arab Emirates, representing 
11.3% of the EAEC isolates recovered during 1 year. All 
five isolates carried the WaCTX-M-15. This is the first 
detailed description and characterization of ESBL produc-
tion in EAEC and also the first report of CTX-M-producing 
organisms encountered on the Arabian Peninsula 
(Sonnevend et al., 2006). 
Australia 
The CTX-M-3 type (3-lactamase from a nosocomial K. 
pneumoniae isolate was reported for the first time in 
Australia by Paterson et al. in 2003. 
Africa 
The first report from Africa of a CTX-M-type (3-lactamase 
(CTX-M-12) was from Kenya in 2001 This study involved 
nine K. pneumoniae isolates from new born babies at 
Kenyatta National Hospital in Nairobi, Kenya (Kariuki et 
al., 2001). CTX-M-15 reported in 2005 in Africa, was 
found in 5 E. coli isolates and 1 K. pneumoniae isolate 
out of 19 ESBL producing isolates in Tanzania. In this 
study only 1 Salmonella isolate was also ESBL positive, 
but did not produce the CTX-M enzyme (Blomberg et al., 
2005). In 2005 Gangoue-Pieboji et al. reported the 
emergence of CTX-M-15 in three isolates of K. pneumo-
niae and E. coli derived from patients with urinary tract 
infections acquired during hospitalization in Cameroon. In 
Nigeria in 2005 ESBLs were characterized from 30 
selected multi-drug resistant K. pneumoniae strains isola-
ted from patients with community acquired urinary tract 
infections from Southwest Nigeria. The 30 strains 
produced multiple (3-lactamases with 57% producing 
CTX-M (3-lactamase. Only 2 CTX-M type genes were 
sequenced and were found to produce CTX-M-15 (Soge 
et al., 2006). The presence of (3-lactamases with an 
extended spectrum of activity in 46 clinical E. coli isolates 
in Egypt was reported in 2006. 28 out of 46 strains 
produced CTX-M (3-lactamases. CTX-M-14,-15 and -27 
were found, with CTX-M-15 (25 out of the 28 strains) 
being the most prevalent (Al- Agamy et al., 2006). In 
2001 a Salmonella isolate from the military hospital in 
Tunisia was found to produce a CTX-M-3 ESBL. CTX-M-
27 production in 16 isolates of S. enterica serotype 
Livingstone were the cause of a nosocomial outbreak in 
the neonatal ward of Farhat Hached Hospital, in Tunisia 
in 2002 (Godet et al., 2005). In 2003 Paterson et al. 
identified a CTX-M-2-type and a CTX-M-3-type (3-
lactamases in 2 separate K. pneumoniae isolates from 
South Africa. This was the first report of CTX-M-type (3-
lactamases in South Africa. CTXM-37 was also reported 
in 2006 in Durban, South Africa from three S. enterica 
serotype Isangi strains. This study involved 59 putative 
ESBL Salmonella strains from a tertiary hospital in 
Durban (Govinden et al., 2006). A further study in 2006 of 
ESBL positive Salmonella sp. revealed the presence of a 
CTX-M-38 enzyme (Genbank accession number 
DQ864700). A study in Central African Republic was 
conducted between 2003 and 2005 to determine the fre-
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quency of ESBLs and to characterize (3-lactamases in 
450 Enterobacteriaceae isolates at the Institut Pasteur de 
Bangui. Of the 4% of ESBL producing strains, CTX-M-15 
was present in 10 E coli and 1 K. pneumoniae isolate, 
whilst CTX-M-3 was present in only 1 E aerogenes 
isolate (Frank et al., 2006). Four sequential ESBL-
producing isolates of K. pneumoniae were detected 
during routine culture and susceptibility tests in the 
Ampath service laboratory in Cape Town, South Africa. 
The first and fourth isolates were susceptible to 
ertapenem, whereas the second and third were resistant. 
All 4 isolates belonged to the same strain and produced a 
group 1 CTX-M enzyme (Elliott et al., 2006). 
BIOCHEMICAL EVOLUTION 
Most CTX-M enzymes exhibit a much greater hydrolytic 
efficiency against cefotaxime than against ceftazidime. In 
the cefotaxime intermediate structure with Toho-1, resi-
dues Pro167, Asn170, Ser237, Asp240, and Arg274 are 
surrounded the bulky side chain of cefotaxime. In addition 
both side oxygens of Asp240 interact with the amino 
group in the aminothiazole ring, which may be involved in 
the binding of cefotaxime (Shimamura et al., 2002). In the 
CTX-M ESBLs, unlike those of TEM- and SHV-, increa-
sed activity against the bulky third generation cephalo-
sporins, especially ceftazidime appears to occur not from 
gross enlargement of the active site, but from increased 
flexibility of the 33 strand and possibly other regions. This 
increased flexibility is correlated with higher ceftazidi-
mase activity and lower stability (Chen et al., 2005). 
The presence of Lys and Arg residues at position 240 
are known to increase the enzymatic activities of the TEM 
and SHV ESBLs against ceftazidime. The Lys and Arg 
residues are positively charged and can form an electro-
static bond with the carboxylic acid group on oxyimino 
substituents of ceftazidime. Neutral residue Gly240 is not 
able to form electrostatic interactions with 3-lactams but 
could favor the accommodation of the oxyimino-ceftazi-
dime side chain (Bonnet, 2004). Residue Gly240 is pre-
sent in the ESBLs PER, VEB-1, and BES-1, which have 
hydrolytic activity against ceftazidime (Delmas et al., 
2006). 
Amino acid positions 240 and 167 seem to be involved 
in the evolution of CTX-M enzymes. CTX-M-15,-16,-27 
and -32, which derive from CTX-M-3, -14,-9 and - 1 , 
respectively, by a Gly240Asp substitution, has greater 
catalytic efficiencies against ceftazidime (Bonnet, 2004). 
Munday et al. (2004) reported that CTX-M-25, which also 
has an Asp240Gly substitution, resulted in good enzy-
matic affinity towards ceftazidime, whilst CTX-M-26 which 
lacks the Asp240Gly substitution showed almost no 
activity towards ceftazidime. Comparison of the amino 
acid structures of other CTX-M enzymes available in the 
GenBank database reveals a glycine molecule at position 
240 for CTX-M-28,-29,-33, -41 and -43, suggesting that 
these enzymes may also have ceftazidimase activity. To 
confirm the importance of Asp240-Gly substitution in the 
hydrolysis of ceftazidime, Cartelle et al. (2004) replaced 
the Gly240 with Asp in CTX-M-32 by using site directed 
mutagenesis. A lower MIC and lower catalytic efficiency 
was detected with the CTX-M-32 mutant. However site 
directed mutagenesis studies of CTX-M-9 by Aumeran 
and colleagues demonstrated that a substitution at posi-
tion 240 of Asp240Lys (instead of Asp240Gly) was simi-
lar to mutations that promote ceftazidime activity found in 
the TEM and SHV ESBLs but did not result in increased 
hydrolysis of cetazidime for this enzyme (Munday et al., 
2004). A random mutagenesis technique was used by 
Delmas et al. (2006) to predict the evolutionary potential 
of CTX-M-9 towards the acquisition of improved catalytic 
activity against ceftazidime. The mutants conferred 1 - to 
128- fold higher MICs of ceftazidime than the parental 
enzyme CTX-M-9. In addition to other mutants the 
substitutions Asp240Gly and Pro167Ser were noted. The 
kinetic constants of the three most active mutants revea-
led two distinct ways of improving catalytic efficiency 
against ceftazidime also suggesting that the CTX-M 
enzymes harbouring the substitution Asp240Gly are the 
most probable phylum for new mutants conferring the 
highest level of resistance to (3-lactams (Delmas et al., 
2006). 
CTX-M-19, which derives from CTX-M-18 by a 
Pro167Ser substitution, is able to hydrolyze ceftazidime 
more efficiently than cefotaxime (Poirell et al., 2001). In 
laboratory-derived mutants of TEM-1, PSE-4 and BPS-1, 
a very similar mutation, Pro167Ser has been shown to be 
closely associated with ceftazidime resistance. CTX-M-23 
with a Pro167Thr substitution is also associated with a 
higher level of resistance to ceftazidime than to cefota-
xime. Even though residue 167 is not a direct part of the 
catalytic mechanism, this position seems to have a direct 
influence on substrate specificity (Sturenburg et al., 
2004). 
CONCLUSION 
The widespread use of ceftriaxone and/or cefotaxime has 
been proposed as a reason for the emergence of CTX-M 
enzymes. The increased frequency of isolation and 
reporting of CTX-M ESBLs is alarming and is likely to 
represent only the tip of the iceberg for the under-
developed continents where technology for the analysis 
of ESBL enzymes is scarce. The loss of the oxyimino-
cephalosporins for treatment of infections represents a 
serious problem that seems to reach unprecedented 
levels globally (Munday et al., 2004). CTX-M enzymes 
are now endemic in many countries with both nosocomial 
and community emergence. The diversity of the CTX-M 
enzymes is noted especially in the Far East, Eastern 
Europe and Western Europe and some ESBL studies 
have identified CTX-M enzymes as the most prevalent 
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ESBL. The emergence of novel CTX-M p-lactamases in 
several countries is noted as opposed to the transfer of 
established CTX-M genes from one country to another, 
suggestive of a de novo dissemination of CTX-M genes. 
Despite many publications on ESBL enzymes, insight in 
the quantitative global distribution is lacking. A co-ordi-
nated study to obtain this information is urgently needed. 
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Abstract 
Extended-spectrum p-lactamases (ESBLs) were characterized in 41 Salmonella spp. isolates from patients admitted to a pediatric ward of 
a tertiary hospital in Durban, South Africa. The most common (17/41) serotype was Salmonella enterica serotype Typhimurium, followed 
by 5". enterica serotype Isangi (16/41), S. enterica serotype Saint-paul (2/41), S. enterica serotype Kissi (2/41), S. enterica serotype Kivu 
(2/41), and S. enterica serotype Reading (1/41). All isolates were resistant to ampicillin, amoxicillin-clavulanate, piperacillin, ceftazidime, 
and aztreonam but susceptible to meropenem. SHV-12 found in 39% of the isolates was the most common ESBL. TEM-63 was produced in 
29%andTEM-116 in 10% of the isolates, and TEM-131 was found in 1 isolate. Other ESBLs that were identified included SHV-2 (n = 2), 
CTX-M-3 (n = 1), CTX-M-15 (n = 2), and CTX-M-37 (n = 5). In addition, CMY-2 (n = 3) and the OXA-l(n = 1) p-lactamase were also 
detected. The diversity of ESBLs suggests that its incidence in Salmonellae needs to be monitored. 
© 2008 Elsevier Inc. All rights reserved. 
Keywords: Salmonella spp.; Extended-spectrum p-lactamase; Multidrug resistance 
1. Introduction 
Salmonellae are major pathogens in humans as well as in 
animals and comprise more than 2000 serotypes. The enteric 
fever salmonellae including Salmonella enterica serotype 
Typhi are strict human pathogens, whereas all other serotypes 
are primarily pathogens of other mammals but may also cause 
disease in man. Nonenteric fever salmonellae are implicated 
in foodborne gastroenteritis worldwide. Although antibiotics 
are not usually recommended in cases of salmonella 
enterocolitis, they become an essential part of management 
if the infection spreads beyond the gut. Invasive complica-
tions including meningitis, arthritis, and deep-seated 
abscesses are more common in infants, the elderly, and 
immunocompromised people (Yates and Amyes, 2005). 
Because there is widespread resistance against conventional 
* Corresponding author. Tel.: +27-31-2607413; fax: +27-31-2607792. 
E-mail address: govindenu@ukzn.ac.za (G. Usha). 
antibiotics such as ampicillin, chloramphenicol, and cotri-
moxazole, these can no longer be used for empiric treatment 
(Su et al., 2004). Invasive disease is, therefore, treated with 
fluoroquinolones or extended-spectrum cephalosporins 
(Yates and Amyes, 2005). Ceftriaxone is commonly used to 
treat children with invasive infections or severe diarrhea 
caused by salmonellae; however, ceftriaxone-resistant sal-
monellae in humans as well as animals have frequently been 
reported from all inhabited continents including Africa 
(Kariuki et al., 2005; Kruger et al., 2004; Li et al., 2005). A 
recent study of multidrug-resistant Salmonella spp. in Kuwait 
and the United Arab Emirates reported a 5-fold rise in the 
resistance rate to the 3rd-generation cephalosporin ceftriax-
one and cefotaxime (Rotimi et al., 2008). 
Extended-spectrum p-lactamases (ESBLs) are predomi-
nantly associated with Enterobacteriaceae. ESBLs in salmo-
nellae in Africa were 1st described in 1988 (Hammami et al., 
1991) and are increasing in prevalence worldwide (Morris 
et al., 2006). ESBLs reported in Salmonella spp. include 
TEM, SHV, and CTX-M (Su et a l , 2004). In this study, we 
0732-8893/$ - see front matter © 2008 Elsevier Inc. All rights reserved. 
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characterized the ESBLs in a collection of putative ESBL-
positive Salmonella spp. from a tertiary hospital in Durban, 
Kwazulu Natal (KZN), South Africa. 
2. Materials and methods 
2.1. Bacterial strains 
Fifty-nine putative ESBL-positive isolates of Salmonella 
spp. were cultured from stool samples of neonates presenting 
with acute diarrhea in 2001 at the King Edward VIII hospital 
in Durban. All isolates were serotyped by the hospital 
laboratory using commercially available antisera (Bioweb, 
Johannesburg, South Africa) according to the Kauffman-
White scheme for salmonella serotyping (Kauffman, 1972; 
Popoff, 2001). Escherichia coli 25922 was used as the 
control for susceptibility testing. Klebsiella pneumoniae 
ATCC 700603 was used as the control for ESBL detection. 
For polymerase chain reaction (PCR) studies, E. coli MEN 
(Barthelemy et al., 1992), E. coli CF 204 (Sirot et al., 1987), 
and E. coli CF 1004 (Chanal et al., 1996) provided positive 
controls for CTX-M-, TEM-, and SHV-type (5-lactamases, 
respectively, with distilled water being the negative control. 
2.2. Susceptibility testing and ESBL detection 
Disc diffusion susceptibility tests for ampicillin, amox-
icillin-clavulanate, ampicillin-sulbactam, piperacillin, cef-
tazidime, cephalothin, ceftriaxone, cefepime, cefuroxime, 
cefotaxime, cefoxitin, meropenem, aztreonam, and piper-
acillin-tazobactam were performed according to the 
National Committee for Clinical Laboratory Standards 
(2003) guidelines. Results were read with the Biomic 
automated reading system (Giles Scientific, New York, 
NY). Putative ESBL-positive isolates were determined at 
the hospital laboratory by the double disc synergy/disc 
approximation method using ceftazidime, amoxicillin-
clavulanate, and cefotaxime on Mueller-Hinton agar. 
ESBL production was further determined by the E-test 
method according to the manufacturer's guidelines (AB 
BIODISK, Solna, Sweden). The presence of an ESBL was 
verified by the appearance of a phantom zone or 
deformation of the cefotaxime or ceftazidime ellipse. The 
final sample size of 41 was determined by a positive ESBL 
test in combination with elevated MICs to 1 or more 3rd-
generation cephalosporins. 
2.3. Isoelectric focusing of ^-lactamases 
Bacterial cells were broken by the freeze-thaw method 
(Livennore and Williams, 1996), and isoelectric focusing of 
crude extracts was performed in polyacrylamide gels 
containing ampholines with a p / range of 3.5 to 9.5 
(Amersham Biosciences, Uppsala, Sweden). An isoelectric 
point marker p/ (4.7-10.6) calibration kit served as the 
standard (BDH, England), p-lactamase bands were visua-
lized with nitrocefin (Oxoid, Basingstoke, UK). 
2.4. PCR detection of blaTEM, blastfK blaCrx-M, blaOXA, 
blaCMY, blaD„A, and blaACC genes 
All 41 isolates were screened for the presence of WOTEM, 
blaSUv, blaCTX-M, blaOXA, blaCMY, blaDUA, and blaACc 
genes. Bacteria were grown on Mueller-Hinton agar 
(Biolab, Johannesburg, South Africa) overnight and sus-
pended in distilled water. DNA was extracted by heating the 
suspensions at 95 °C for 5 min. PCR amplification was then 
performed in a Gene Amp 9700 PCR System (Applied 
Biosystems, Foster City, CA). The primers (Inqaba Bio-
technology, Pretoria, South Africa) are described in Table 1. 
PCR conditions for amplification of WGTEM and blaSHV 
genes were carried out as described by Essack et al. (2001). 
The amplification mixture for the detection of Wacrx-M, 
WflcMY, blaOXA, blaDHA, and blaACC genes was prepared in 
a final volume of 50 pL, containing purified water, 2 pL of 
the template DNA, 10 pmol of each primer, and 25 pL of 
master mix (Applied Biosystems). The PCR program for 
blaCTx-M consisted of an initial denaturation step at 94 °C for 
3 min, followed by 25 cycles of DNA denaturation at 94 °C 
for 30 s, primer annealing at 54 °C for 1 min, and primer 
extension at 72 °C for 2 min, with a final extension step at 
72 °C for 7 min. The PCR conditions used for the detection 
of blaCMY, blaaxA, blauuA, and blaACC genes were as 
previously described (Kaye et al., 2004; Perez-Perez and 
Hanson, 2002; Zhao et al., 2001). Five-microliter aliquots 
of PCR product were analyzed by gel electrophoresis. Gels 
were stained with ethidium bromide at 10 pg/mL and 
photographed under ultraviolet illumination. 
2.5. Sequencing 
The primers used for DNA sequencing are shown in 
Table 1. Sequencing of the amplified products was 
performed with the Spectrumedix model SCE 2410 auto-
mated sequencer (Spectrumedix, State College, PA), incor-
porating the ABI Big Dye Terminator Cycle Sequencing kit 
version 3.1 (Applied Biosystems). Sequences were analyzed 
using the BLAST 2.0 (Basic Local Alignment Search Tool) 
software available on the website of the National Center for 
Biotechnology Information (http://www.ncbi.nlm.nih.gov/ 
blast/BLAST.cgi, accessed 16 July 2007). 
3. Results 
Table 2 shows the serotypes, isoelectric point(s), the 
extrapolated MIC values of selected p-lactams, and the 
various p-lactamases identified in the study. The most 
common serotype among the 41 isolates was S. enterica 
serotype Typhimurium (17/41), followed by S. enterica 
serotype Isangi (16/41). All 41 isolates were resistant to 
ampicillin (>48 pg/mL), amoxicillin-clavulanate (48 to 
>64 pg/mL), piperacillin (>512 pg/mL), and ceftazidime (64 
to >128 pg/mL) but susceptible to meropenem (<0.5 to 
1 pg/mL). Tazobactam was the most effective inhibitor 
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Table 1 
Primers used in this study 
Primer Sequence (5'-3') Purpose of primer Reference 
TEM 1 (F) 
TEM 2 (R) 
TEM 3 (R) 
TEM 4 (R) 
TEM 5 (F) 
SHV 1 (F) 
SHV 2 (R) 




































































Essack et al. (2001) 




Govinden et al. (2006) 
Govinden et al. (2006) 
Edelstein et al. (2003) 
Edelstein et al. (2003) 
Zhao etal. (2001) 
Zhao etal. (2001) 
Mocktar et al. (2008) 
Mocktar et al. (2008) 
Mocktar et al. (2008) 
Mocktar et al. (2008) 
Kaye et al. (2004) 
Kaye et al. (2004) 
Perez-Perez and Hanson (2002) 
Perez-Perez and Hanson (2002) 
Perez-Perez and Hanson (2002) 
Perez-Perez and Hanson (2002) 
F = forward primer; R = reverse primer; amp = amplification; seq = sequencing. 
because resistance to piperacillin-tazobactam was found in 
only 1 isolate. TEM-1 (51%) was the most predominant 
p-lactamase produced, and it was found most frequently in 
combination with SHV-12 with pi values ranging from 5.4 to 
6.1 and 7.6 to 8.4, respectively. Isolates 509, 541, and 640 
produced TEM-1 and CTX-M-37 (Govinden et al., 2006). 
CTX-M-15 was only found in 2 isolates, 464 and 580, 
whereas CTX-M-3 was found in a single isolate. OXA-1 with 
CTX-M-37 and TEM-1 was produced only in isolate 509b. A 
unique combination of TEM-63, CTX-M-37, and the AmpC-
type p-lactamase, CMY-2 was found in isolate 376. CMY-2 
was also found in isolate 262 with TEM-1 and SHV-2 and in 
isolate 370 with TEM-63. All isolates with CMY-2 had 
elevated cefoxitin MICs of >96 ug/mL. The other AmpC-
type (J-lactamases, DHA and ACC, were not found. To our 
knowledge, this is the 1st report of such p-lactamase gene 
combinations in Salmonella spp. from South Africa. 
4. Discussion 
In 2007, The Enteric Diseases Reference Unit of the 
National Institute for Communicable Diseases in South 
Africa reported 17.7% of nontyphoidal salmonella isolates 
(n - 1502) to be ESBL producers, and resistance to 5 or more 
antimicrobial agents was observed in 33.8% of the isolates 
(Keddy, 2008). The 1st salmonella strains with ESBLs in 
Africa were identified in 1988 in Tunisia (Hammami et al., 
1991). An ESBL study of 160 Salmonella spp. from 13 
hospitals in South Africa was reported in 2004 to produce 
15.6% of TEM or SHV ESBLs (Kruger et al., 2004). A 
nosocomial outbreak of salmonella infection in pediatric 
patients caused by Salmonella Isangi producing ESBLs was 
1st reported from the Chris Hani Baragwanath Hospital, 
Johannesburg, South Africa, in 2006 (Wadula et al., 2006). 
Salmonellae have, thus, acquired a variety of ESBLs (TEM, 
SHV, CTX-M) and may no longer be described as a rare 
producer of ESBLs. 
TEM-63 in K. pneumoniae was reported for the 1 st time 
from Durban, South Africa, in 2000 by Essack et al., and 
there were further reports in South Africa of TEM-63 in 
strains of Proteus spp., Enterobacter spp., E. coli, Entero-
bacter cloacae (Gray et al., 2006), and Salmonella spp. 
(Kruger et al., 2004). An ESBL study in sub-Saharan Africa 
in Tanzania detected TEM-63 in E. coli and K. pneumoniae 
(Blomberg et al., 2005). The 1st report of TEM-63 outside 
the African continent in Salmonella Isangi, from a single 
patient, was also found in an ESBL study in Netherlands in 
2005. It is unknown if the patient had traveled to South 
Africa (Hasman et al., 2005). In this study, 29% (12/41) of 
the isolates contained TEM-63 and was most commonly 
found in Salmonella Isangi. The amino acid changes of 
TEM-63 compared with TEM-1 were L21F, which lies in the 
signal peptide, E104K, which occurs in many TEM ESBLs, 
and R164S, which widens the binding cavity to accom-
modate the bulky side chains of oxyimino-aminothiazolyl 
cephalosporins. The R164S substitution also leads to high 
resistance to ceftazidime but low levels of resistance to 
cefotaxime (Orencia et al., 2001), as can be seen with the 9 
isolates (216, 256, 259, 296, 420, 482, 793, 895, and 1048) 
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Table 2 
Characterization of ESBL-positive Salmonella strains 
S. enterica serotype 
ND 
Typhimurium 
1,4,5,12; i l , 2 b 
lsangi6,7 14:d 1,5 b 
Saint-paul 1,4,5,12; eh l , 2 b 
Kivu6,7:d 1,6 b 
Kissi6.7:d 1,2 b 
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TZP = piperacillin-tazobactam; CEF = cephalothin; CXM = cefuroxime; FOX = cefoxitin; CRO = ceftriaxone; CTX = cefotaxime; CAZ = ceftazidime; FEP = 
cefepime; ATM = aztreonam; ND = serotype could not be determined. 
a Hospital isolate number. 
b Antigenic formula (somatic [O] antigen, flagellar [H] antigen phase 1, flagellar [H] antigen phase 2). 
c Govinden et al., 2006. 
expressing only TEM-63 with ceftazidime MICs of 64 to 
>128 ug/mL and cefotaxime MICs of 4 to 8 ug/mL. The 
M182T mutation is found only in combination with other 
amino acid substitutions, suggesting that it may correct 
defects introduced by other mutations that alter the 
specificity, thus, conferring a selective advantage during 
the evolution of drug resistance (Sideraki et al., 2001). 
TEM-131 from Salmonella spp. in South Africa was 1st 
reported in an ESBL study by Kruger et al. (2004). Only 
isolate 467 produced TEM-131, which differs from TEM-
63 by 1 amino acid substitution, A237T. As reported by 
Knox (1995), a clear indication of the utility of threonine at 
position 237 comes from a crystallographic mapping of the 
binding of cefotaxime to the structurally homologous DD-
peptidase. Cefotaxime with its branched oximino substi-
tuent was found tilted out of the binding site and unable to 
form the expected hydrogen bond to the backbone CO 
group at position 237. Instead, cefotaxime's acylamino NH 
group donates a hydrogen bond to the side-chain OH group 
of threonine, which exists at this position in the DD-
peptidase. Thus, the replacement of A237 with a hydrogen 
bond acceptor such as threonine enhances the binding of 
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cefotaxime and ceftazidime (Knox, 1995). TEM-131 also 
has the R164S substitution with the ceftazidime MIC of 
>128 ng/mL and the cefotaxime MIC of 48 [ig/mL. Four of 
the isolates (948, 954, 317, and 288) produced TEM-116, 
which differs from TEM-1 by 2 amino acid changes: V84I 
and A184V. This is the 1st report of TEM-116 from Sal-
monella spp. in South Africa. TEM-116, which was also 
identified in Korea, was reported by Jeong et al. (2004) to 
have possibly evolved directly from TEM-1. 
SHV-12 in 39% (16/41) of isolates was produced in 
combination with a TEM-type p-lactamase. The 1st report of 
SHV-12 in the genus Salmonella, published in 2001, 
described 5 strains of S. enterica serotype Keurmassar, 
which were isolated in 2000 in Dakar, Senegal (Weill 
et al., 2004). SHV-12 has a combination of amino acid 
changes of SHV-2, SHV-2a, and SHV-5 (http://www.lahey. 
org/Studies/, accessed July 16, 2007). Except for SHV-2 in 
isolate 262 and 402, SHV-2a and SHV-5 were not detected, 
suggesting that SHV-12 may have evolved from SHV-2 or it 
could have been acquired from other strains such as K. 
pneumoniae. Kruger et al. (2004) reported SHV-12 and 
SHV-5 from Salmonella spp. in South Africa. 
CTX-M-3, CTX-M-15, and CTX-M-37 were detected in 
this study. CTX-M-37 was 1st reported in 2005 from 
Mongolia and then in South Africa (Govinden et a l , 2006). 
Several countries have reported the occurrence of CTX-M-
15 either in an outbreak or from ESBL studies (Govinden 
et al., 2007). CTX-M-15 was only found in 2 isolates in 
this study. The expression of blaCMY_2 gene was reported as 
being responsible for most ceftriaxone resistance in 
Salmonella spp. This gene was 1st identified in a 
multiresistant S. enterica serotype Senftenberg strain 
isolated in 1994 (Li et a l , 2005). Although ceftriaxone 
resistance was noted in this study, it was not solely 
attributable to CMY-2, which was detected in only 3 of the 
isolates that had MICs of 32 to 96 jig/mL for ceftriaxone. 
According to the South African Standard Treatment 
Guidelines (STG) and Essential Drugs List (EDL) 
(National Essential Drugs List Committee, 2006), ceftriax-
one is prescribed for pediatric use in salmonella infections, 
and quinolones are used if there is a cephalosporin allergy. 
Ciprofloxacin and ceftriaxone are prescribed for adults. 
Ceftriaxone resistance was found in 4 1 % (17/41) of the 
isolates, and the treatment with ceftriaxone for pediatric 
and possibly adult salmonella infections would soon be 
compromised. Ceftriaxone should not be used therapeuti-
cally for ESBL-producing Salmonella spp. According to 
the results of this study, the STG and the EDL needs to be 
revised urgently to maintain the efficacy of ceftriaxone. 
This study shows that ESBL-positive Salmonella spp. can 
be multidrug resistant, with the propensity to harbor TEM, 
SHV, CTX-M, CMY, and OXA ^-lactamases in unique 
combinations, which is not frequently reported. Failure to 
identify drug-resistant salmonellae may affect the choice of 
appropriate alternative antibiotics in the treatment of 
patients with invasive salmonellosis (Su et a l , 2004). 
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Abstract 
The high prevalence of resistance to nalidixic acid and reduced susceptibility to 
ciprofloxacin of Salmonella spp. obtained from stool samples of neonates 
presenting with acute diarrhea in 2001 at the King Edward VIII hospital in 
Durban, South Africa, prompted this study to determine if there were any 
mutations in the QRDR of these isolates and to search for the qnrA gene. All 
isolates with nalidixic acid MICs > 48 ug/ml had the single mutation D87N, or 
D87G in the QRDR of the gyrA gene, and only 2 strains had an additional 
mutation; S83L and S83F respectively. The mutation S83T was present in only 
one isolate with the nalidixic acid MIC of 10 ug/ml whilst the 6 other strains with 
nalidixic acid MICs < 10 ug/ml had no changes in the QRDR of the gyrA gene. 
The qnrA gene was not found. These findings indicate that there are mutations in 
the gyrA of Salmonella isolates which could contribute to resistance to nalidixic 
acid with reduced susceptibility to ciprofloxacin and there is the co-expression of 
quinolone and extended-spectrum ft-lactam resistance among Salmonella spp. 
Keywords: quinolone resistance, mutations in gyrA 
Introduction 
In gram-negative bacteria the principal target of quinolone including 
fluoroquinolone activity is the type II topoisomerase, DNA gyrase. DNA gyrase is 
a tetramer composed of two GyrA subunits (encoded by gyrA gene) and two 
GyrB subunits (encoded by gyrB gene) (Kilmartin et al., 2005). DNA gyrase 
catalyses the negative supercoiling of DNA and is therefore essential for 
maintenance of DNA topology. Topoisomearse 1V is also a tetrameric enzyme 
consisting of two ParC and two ParE subunits and is involved in the segregation 
of replicated daughter chromosomes during DNA replication. Topoisomerase 1V 
is a homologue of DNA gyrase and the parC and parE genes have strong 
sequence identity to gyrA and gyrB. Fluoroquinolones stabilize the breaks in the 
DNA made by the DNA gyrase or topoisomerase 1V, and the resulting 
drug/enzyme/DNA complex inhibits DNA synthesis (Hopkins et al., 2005). 
The isolates were serotyped using commercially available antisera (Bioweb, 
South Africa) according to the Kauffman-White scheme for Salmonella serotyping 
(Kauffman, 1972, Popoff, 2001). 
Susceptibility testing 
Disc diffusion susceptibility tests for nalidixic acid and ciprofloxacin, were 
performed according to NCCLS guidelines (2003). Results were read with the 
Biomic automated reading system (Giles Scientific, New York). 
PCR detection of gyrA and qnrA genes 
Amplification of the gyrA and QnrA genes were done with primers gyrA- F 5' 
TGTCCGAGATGGCCTGAAGC 3', gyrA- R 5' CGTTGATGACTTCCGTCAG 3' 
(Giraud et al., 1999) and QP1- 5' GATAAAGTTTTTCAGCAAGAGG 3' and QP2 -
5' ATCCAGATCGGCAAAGGTTA 3' (Jacoby et al., 2003) respectively. Strains 
were grown overnight at 37°C in Mueller-Hinton broth. 1.5 ml of each culture was 
pelleted and cells were boiled in 200 ul of water. After centrifugation the 
supernatants were kept at -20°C. PCR was performed in a total volume of 50 ul, 
which contained 5 ul of supernatant, 25 ul of master mix (Applied Biosystems), 
25 pmol of each primer and water. After an initial denaturation of 3 min at 94°C, 
amplification was performed over 30 cycles, each one consisting of 1 minute at 
94°C, 1 minute at hybridization temperature 55°C, and 1 min at 72°C, with a final 
extension step of 10 min at 72°C. Five-microliter aliquots of PCR product were 
analysed by gel electrophoresis with 1 % agarose. Negative controls were PCR 
mixtures with the addition of water in place of template DNA. Gels were stained 
with ethidium bromide at 10 ^g/ml and photographed with UV illumination. 
Sequencing of the amplified products was performed with the SpectruMedix 
model SCE 2410 automated sequencer (SpectruMedix, State College, PA), 
incorporating the ABI Big Dye Terminator Cycle Sequencing kit version 3.1 
(Applied Biosystems, Foster City, CA). Sequences were analysed using the 
BLAST 2.0 (Basic Local Alignment Search Tool) software 
(http://www.ncbi.nlm.mih.gov/Blast/; accessed September 2007. 
Results and Discussion 
Of the 29 isolates studied, 37% (22/59) were resistant to nalidixic acid with MICs 
> 48 ug/ml, whilst 63 % (37/59) fell in the susceptible range with MICs from 4 to 
10 ug/ml. All the isolates were susceptible to ciprofloxacin with MIC ranging from 
0.125 ug/ml to 0.5 ug/ml. Sixteen resistant and 5 susceptible isolates to nalidixic 
acid were ESBL positive. Sequencing identified mutations in the QRDR of gyrA 
as per table. Mutations in gyrA were noted for ESBL positive and negative 
strains with resistance to nalidixic acid; the exception was isolate 376 that was 
ESBL positive, susceptible to nalidixic acid and had a S83T mutation. No positive 
amplification product was obtained for the qnrA gene. 
All isolates with nalidixic acid MICs > 48 had the single mutation D87N, or D87G 
in the QRDR of the gyrA gene, and only 2 strains; 580 and 695 had an additional 
mutation; S83L and S83F respectively. The mutation S83T was present in only 
one strain that had the nalidixic acid MIC of 10 ug/ml whilst the 6 other strains 
with nalidixic acid MICs < 10 ug/ml had no changes in the QRDR of the gyrA 
gene. An increase in the MIC to ciprofloxacin was noted in most strains with 
ciprofloxacin MIC > 0.125 ug/ml. Although ciprofloxacin MICs of < 1 ug/ml and > 
4 ug/ml are accepted breakpoints for susceptibility and resistance to salmonellae, 
it has been suggested that fluoroquinolone-susceptible strains that test resistant 
to nalidixic acid may be associated with clinical failure or delayed response in 
fluoroquinolone-treated patients with extraintestinal salmonellosis (CLSI, 2008). 
Susceptibility testing for nalidixic acid is therefore encouraged although this drug 
is not used for the treatment of extraintestinal Salmonella infections. (Rodriguez 
et al., 2005). A single mutation in gyrA of Salmonella may be sufficient to cause 
high-level resistance to nalidixic acid but additional mutations may be required to 
attain high level fluoroquinolone resistance. Levy et al., (2004) showed that the 
relative frequency of mutations depended on the particular fluoroquinolone used 
for selection. Selection with enrofloxacin was more likely to yield S83F mutations, 
while selection with ciprofloxacin or nalidixic acid favoured recovery of D87G 
mutations (Hopkins et al., 2005). The most frequent mutations noted in this study 
were D87G and D87N. There is also a speculation that the reduced quinolone 
susceptibility may be due to decreased permeability or the presence of efflux 
pump mechanisms as exposure to low level quinolones can lead to inactivation of 
the efflux pump system and a reduction in susceptibility, even when there is no 
mutation in gyrA (Cebrian et al ., 2005). 
Quinolone resistance in Enterobacteriaceae appears to be a staggered process, 
where an initial mutation in gyrA produces nalidixic acid resistance and 
decreased susceptibility to fluoroquinolones and facilitates the occurrence of a 
second mutation in the same gene or in other quinolone target encoding genes 
that will lead to full resistance. Therefore resistance to naldixic acid could be a 
good predictor for the emergence of fluoroquinolone resistance (Aznar et al., 
2007). These findings indicate that there are mutations in the gyrA of Salmonella 
isolates which could contribute to resistance to nalidixic acid with increased MICs 
to ciprofloxacin. In addition there is the co-expression of quinolone and extended-
spectrum fl-lactam resistance among Salmonella spp. The continued use of 
nalidixic acid and ciprofloxacin could result in further mutations in the DNA 
gyrase and increasing resistance to these antibiotics. 
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* Serotype could not be determined 
CHAPTER THREE - LIMITATIONS, CONCLUSIONS, RECOMMENDATIONS 
3.1 LIMITATIONS 
The PER-1 p-lactamase was not considered in this study as it is endemic to Turkey 
and Argentina. The carbapenemase (KPC-type) was reported in a Salmonella 
serotype Cubana isolate in a hospital in the United States in 2003. It has not been 
reported since and was thus not included in this study. Other examples of non 
TEM, non SHV ESBLs that have been described but not reported in Salmonella 
such as GES, BES, SFO, TLA, IBC and VEB-1 were also not included in this study 
(http://www.lahey.org/Studies/; Accessed 17 August 2008; Paterson and Bonomo, 
2005). 
3.2 CONCLUSIONS 
p-lactamases were characterized in 41 Salmonella spp. isolates from patients in a 
pediatric ward of a tertiary hospital in Durban South Africa. 
• The most common serotype (17/ 41) was Salmonella enterica serotype 
Typhimurium. 
• All isolates were multi-drug resistant with meropenem being the most effective 
(3-lactam antibiotic. Ceftriaxone resistance was found in 17/41 (41 %) of the 
isolates. Ceftriaxone should thus not be used therapeutically for ESBL 
producing Salmonella spp. and the South African STG and the EDL needs to 
be reviewed in this regard. 
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• TEM-1 was the most predominant 3-lactamase. The evolution of the TEM-type 
B-lactamase was evident in the identification of TEM-1, TEM-63, TEM-116 and 
TEM-131. 
• The most common ESBL was SHV-12 whilst SHV-2 was found only in 2 
isolates. 
• CTX-M-3, -15, -37, CMY-2 and the OXA-1 3-lactamases were also detected. 
• This is the first report of TEM-116 and CTX-M-37 in Salmonella spp. 
• The unique co-expression of TEM-63, CTX-M-37 and the AmpC-type 6-
lactamase CMY-2, is to our knowledge, the first report of such (3-lactamase 
gene combinations in Salmonella spp. globally. 
• All isolates with nalidixic acid MICs > 48 ug/ml had the single mutation D87N, 
or D87G in the QRDR of the gyrA gene, and only 2 strains had an additional 
mutation; S83L and S83F respectively. The qnrA gene was not found. 
• The co-expression of quinolone and extended-spectrum U -lactam resistance 
among Salmonella spp. was noted. 
This study shows that ESBL positive Salmonella spp. can be multi-drug resistant 
with the propensity to harbour TEM, SHV, CTX-M, CMY and OXA B-lactamases in 
unique combinations. Co-resistance to quinolones and ESBLs will limit therapeutic 
options for Salmonella infections. Failure to identify drug-resistant salmonellae 
may affect the choice of appropriate antibiotics in the treatment of patients, 
especially pediatric patients with invasive salmonellosis. 
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3.3 RECOMMENDATIONS FOR FURTHER STUDY 
Detection of different classes of R>-lactamases in fi-lactam resistant Salmonella 
spp. is of critical clinical importance, since it can often provide valuable information 
to clinicians leading to more effective and appropriate use of antimicrobials. It also 
serves as a powerful epidemiologic tool for the infection control purpose (Doi and 
Paterson, 2007). 
There is very little published information on fluoroquinolone, ^.-lactamase or ESBL 
studies on Salmonella spp. in South Africa. Focused surveillance studies are 
needed in hospitals and the community to determine and monitor the extent and 
spread of resistance in Salmonella. Studies should be inclusive of ESBL 
identification on the molecular level and other types of resistance with emphasis on 
the mechanisms involved. The use of ceftriaxone, quinolones and fluoroquinolones 
needs to be closely monitored. 
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